{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:25:01Z","timestamp":1782512701896,"version":"3.54.5"},"reference-count":329,"publisher":"Bentham Science Publishers Ltd.","issue":"7","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MC"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec><jats:title>Abstract:<\/jats:title><jats:p>Despite major antimicrobial therapeutic advancements, widespread use and misuse of antimicrobial drugs have increased antimicrobial drug resistance, posing a severe danger to public health. In particular, the emergence of multidrug-resistant bacteria has provided considerable difficulty in the treatment of pathogenic infections. As a result, the creation of novel drugs to treat resistant bacteria is one of the most significant disciplines of antimicrobial research today. TB therapy has recently gained a lot of attention, in addition to developing novel and efficient antibacterial drugs to battle multidrug-resistant illnesses. The use of a different class of drugs, such as well-known drugs, their derivatives, and various new heterocyclic compounds like nitroimidazoles, imidazole analogues, triazoles, imidazopyridines, quinolines, purines, as well as thioactomycin, mefloquine, deazapteridines, benzothiadiazine and other molecules such as benzoxazines, diterpenoids, tryptanthin and phenazine and toluidine analogues followed by many other classes of compounds and their effects are also discussed. As a result, current and newly found antitubercular drugs and their toxicities and mode of action have been focused.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1573406419666230111111153","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T04:30:56Z","timestamp":1673497856000},"page":"619-652","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Study of Structurally Diverse Currently Used and Recently Developed Antimycobacterial Drugs"],"prefix":"10.2174","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7580-8667","authenticated-orcid":true,"given":"Mazen Mohammed","family":"Almehmadi","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, P.O. Box 11099, Taif, 21944, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2122-4367","authenticated-orcid":true,"given":"Osama","family":"Abdulaziz","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, P.O. Box 11099, Taif, 21944, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0910-4960","authenticated-orcid":true,"given":"Mustafa","family":"Halawi","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Technology, College of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9352-3462","authenticated-orcid":true,"given":"Mohammad","family":"Asif","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Glocal University, Mirazapur pole, Saharanpur, Uttar Pradesh, 247121, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ijtb.2020.02.005","volume":"67","author":"Natarajan A.","year":"2020","unstructured":"Natarajan A.; Beena P.M.; Devnikar A.V.; Mali S.; A systemic review on tuberculosis. Indian J Tuberc 2020,67(3),295-311","journal-title":"Indian J Tuberc"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s13596-011-0020-8","volume":"12","author":"Asif M.","year":"2012","unstructured":"Asif M.; Study of clinically used and recently developed antimycobacterial agents. Orient Pharm Exp Med 2012,12(1),15-34","journal-title":"Orient Pharm Exp Med"},{"key":"ref=3","first-page":"5","volume":"49","author":"Asif M.","year":"2012","unstructured":"Asif M.; Study of currently used antimycobacterials, their analogoues and recently developed agents. IDrugs 2012,49(7),5-19","journal-title":"IDrugs"},{"key":"ref=4","first-page":"1404","volume":"12","author":"Asif M.","year":"2012","unstructured":"Asif M.; A review of antimycobacterial drugs in development. Mini Rev Med Chem 2012,12(13),1404-1418","journal-title":"Mini Rev Med Chem"},{"key":"ref=5","first-page":"783","volume":"82","author":"Okada M.","year":"2007","unstructured":"Okada M.; Kobayashi K.; Recent progress in mycobacteriology. Kekkaku 2007,82(10),783-799","journal-title":"Kekkaku"},{"key":"ref=6","first-page":"11","volume":"1","author":"Surendra S.B.","year":"2010","unstructured":"Surendra S.B.; Arya A.; Sudhir K.S.; Vinita C.; Rama P.T.; Synthesis and antitubercular activity of 5-benzyl-3-phenyl dihydroisoxazole. Inter J Drug Design and Discov 2010,1(1),11-18","journal-title":"Inter J Drug Design and Discov"},{"key":"ref=7","first-page":"94","volume":"5","author":"Omar A.","year":"2008","unstructured":"Omar A.; Ahmed M.A.; Synthesis of Some New 3H-quinazolin-4-One Derivatives as Potential Antitubercular Agents. World Appl Sci J 2008,5(1),94-99","journal-title":"World Appl Sci J"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0040-4020(99)01093-5","volume":"56","author":"El Sayed K.A.","year":"2000","unstructured":"El Sayed K.A.; Bartyzel P.; Shen X.; Perry T.L.; Zjawiony J.K.; Hamann M.T.; Marine natural products as antituberculosis agents. Tetrahedron 2000,56(7),949-953","journal-title":"Tetrahedron"},{"key":"ref=9","year":"2009","unstructured":"World Health Organization (WHO) Global Tuberculosis control epidemiology, strategy, financing. Geneva, Switzerland, 2009"},{"key":"ref=10","year":"2014","unstructured":"Basic facts about Tuberculosis: TB Control: \u2012Yukon Communicable Disease Control Health and Social Services2014","journal-title":"Basic facts about Tuberculosis: TB Control: \u2012Yukon Communicable Disease Control"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s11904-013-0164-x","volume":"10","author":"Kompala T.","year":"2013","unstructured":"Kompala T.; Shenoi S.V.; Friedland G.; Transmission of tuberculosis in resource-limited settings. Curr HIV\/AIDS Rep 2013,10(3),264-272","journal-title":"Curr HIV\/AIDS Rep"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"e2014070","DOI":"10.4084\/mjhid.2014.070","volume":"6","author":"Sulis G.","year":"2014","unstructured":"Sulis G.; Roggi A.; Matteelli A.; Raviglione M.C.; Tuberculosis: epidemiology and control. Mediterr J Hematol Infect Dis 2014,6(1),e2014070","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref=13","year":"2015","unstructured":"Global tuberculosis report World Health Organization (WHO)2015","journal-title":"Global tuberculosis report"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1093\/aje\/kwu320","volume":"181","author":"Vynnycky E.","year":"2015","unstructured":"Vynnycky E.; Sumner T.; Fielding K.L.; Lewis J.J.; Cox A.P.; Hayes R.J.; Corbett E.L.; Churchyard G.J.; Grant A.D.; White R.G.; Tuberculosis control in South African gold mines: mathematical modeling of a trial of community-wide isoniazid preventive therapy. Am J Epidemiol 2015,181(8),619-632","journal-title":"Am J Epidemiol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5588\/pha.14.0087","volume":"4","author":"Acosta C.D.","year":"2014","unstructured":"Acosta C.D.; Dadu A.; Ramsay A.; Dara M.; Drug-resistant tuberculosis in Eastern Europe: challenges and ways forward. Public Health Action 2014,4(2),3-12","journal-title":"Public Health Action"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1086\/505877","volume":"194","author":"Zignol M.","year":"2006","unstructured":"Zignol M.; Hosseini M.S.; Wright A.; Weezenbeek C.L.; Nunn P.; Watt C.J.; Williams B.G.; Dye C.; Global incidence of multidrug-resistant tuberculosis. J Infect Dis 2006,194(4),479-485","journal-title":"J Infect Dis"},{"key":"ref=17","year":"2012","unstructured":"Totally drug\u2012resistant tuberculosis: a WHO consultation on the diagnostic definition and treatment options World Health Organization (WHO)2012","journal-title":"Totally drug\u2012resistant tuberculosis: a WHO consultation on the diagnostic definition and treatment options"},{"key":"ref=18","first-page":"301","volume":"55","year":"2006","unstructured":"Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep Centers for Disease Control and Prevention (CDC)2006,55(11),301-305","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1086\/507542","volume":"43","author":"Masjedi M.R.","year":"2006","unstructured":"Masjedi M.R.; Farnia P.; Sorooch S.; Pooramiri M.V.; Mansoori S.D.; Zarifi A.Z.; AkbarVelayati, A.; Hoffner, S. Extensively drug-resistant tuberculosis: 2 years of surveillance in Iran. Clin Infect Dis 2006,43(7),841-847","journal-title":"Clin Infect Dis"},{"key":"ref=20","first-page":"E070517.1","volume":"12","author":"Migliori G.B.","year":"2007","unstructured":"Migliori G.B.; De Iaco G.; Besozzi G.; Centis R.; Cirillo D.M.; First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill 2007,12(5),E070517.1","journal-title":"Euro Surveill"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/cid\/cir889","volume":"54","author":"Udwadia Z.F.","year":"2012","unstructured":"Udwadia Z.F.; Amale R.A.; Ajbani K.K.; Rodrigues C.; Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012,54(4),579-581","journal-title":"Clin Infect Dis"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3201\/eid1903.120246","volume":"19","author":"Klopper M.","year":"2013","unstructured":"Klopper M.; Warren R.M.; Hayes C.; Gey van Pittius N.C.; Streicher E.M.; M&#xFC;ller B.; Sirgel F.A.; Chabula-Nxiweni M.; Hoosain E.; Coetzee G.; David van Helden P.; Victor T.C.; Trollip A.P.; Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa. Emerg Infect Dis 2013,19(3),449-455","journal-title":"Emerg Infect Dis"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1378\/chest.08-2427","volume":"136","author":"Velayati A.A.","year":"2009","unstructured":"Velayati A.A.; Masjedi M.R.; Farnia P.; Tabarsi P.; Ghanavi J.; ZiaZarifi, A.H.; Hoffner, S.E. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran. Chest 2009,136(2),420-425","journal-title":"Chest"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1128\/IAI.71.12.7099-7108.2003","volume":"71","author":"Kaplan G.","year":"2003","unstructured":"Kaplan G.; Post F.A.; Moreira A.L.; Wainwright H.; Kreiswirth B.N.; Tanverdi M.; Mathema B.; Ramaswamy S.V.; Walther G.; Steyn L.M.; Barry C.E.; Bekker L.G.; Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun 2003,71(12),7099-7108","journal-title":"Infect Immun"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1371\/journal.pmed.0040120","volume":"4","author":"Connolly L.E.","year":"2007","unstructured":"Connolly L.E.; Edelstein P.H.; Ramakrishnan L.; Why is long-term therapy required to cure tuberculosis? PLoS Med 2007,4(3),e120","journal-title":"PLoS Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/S0140-6736(00)03493-0","volume":"356","author":"Hern&#xE1;ndez-Pando R.","year":"2000","unstructured":"Hern&#xE1;ndez-Pando R.; Jeyanathan M.; Mengistu G.; Aguilar D.; Orozco H.; Harboe M.; Rook G.A.W.; Bjune G.; Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection. Lancet 2000,356(9248),2133-2138","journal-title":"Lancet"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.18433\/J36K5K","volume":"11","author":"Kamal A.","year":"2008","unstructured":"Kamal A.; Azeeza S.; Malik M.S.; Shaik A.A.; Rao M.V.; Efforts towards the development of new antitubercular agents: potential for thiolactomycin based compounds. J Pharm Pharm Sci 2008,11(2),56","journal-title":"J Pharm Pharm Sci"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2174\/0929867033368637","volume":"10","author":"Da Silva A.","year":"2003","unstructured":"Da Silva A.; De Almeida M.; De Souza M.; Couri M.; Biological activity and synthetic metodologies for the preparation of fluoroquinolones, a class of potent antibacterial agents. Curr Med Chem 2003,10(1),21-39","journal-title":"Curr Med Chem"},{"key":"ref=29","first-page":"1","volume":"5","author":"Rieder H.L.","year":"2001","unstructured":"Rieder H.L.; Arnadottir T.; Tr&#xE9;bucq A.; Enarson D.A.; Tuberculosis treatment: dangerous regimens? Int J Tuberc Lung Dis 2001,5(1),1-3","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref=30","first-page":"323","volume":"19","author":"Shafii B.","year":"2008","unstructured":"Shafii B.; Amini M.; Akbarzadeh T.; Shafiee A.; Synthesis and antitubercular activity of N3,N5-Diaryl-4-(5-arylisoxazol-3-yl)-1,4-dihydropyridine-3,5-dicarboxamide. J Sci 2008,19(4),323-328","journal-title":"J Sci"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1472-9792(02)00058-6","volume":"83","author":"Espinal M.A.","year":"2003","unstructured":"Espinal M.A.; The global situation of MDR-TB. Tuberculosis (Edinb) 2003,83(1-3),44-51","journal-title":"Tuberculosis (Edinb)"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2165\/00003495-200059020-00002","volume":"59","author":"Telenti A.","year":"2000","unstructured":"Telenti A.; Iseman M.; Drug-resistant tuberculosis. Drugs 2000,59(2),171-179","journal-title":"Drugs"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1016\/j.bmcl.2005.01.085","volume":"15","author":"Kamal A.","year":"2005","unstructured":"Kamal A.; Hari Babu A.; Venkata Ramana A.; Sinha R.; Yadav J.S.; Arora S.K.; Antitubercular agents. Part 1: Synthesis of phthalimido- and naphthalimido-linked phenazines as new prototype antitubercular agents. Bioorg Med Chem Lett 2005,15(7),1923-1926","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.bmc.2005.08.063","volume":"14","author":"Kamal A.","year":"2006","unstructured":"Kamal A.; Srinivasa Reddy K.; Kaleem Ahmed S.; Khan M.N.A.; Sinha R.K.; Yadav J.S.; Arora S.K.; Anti-tubercular agents. Part 3. Benzothiadiazine as a novel scaffold for anti-Mycobacterium activity. Bioorg Med Chem 2006,14(3),650-658","journal-title":"Bioorg Med Chem"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0006-2952(99)00253-1","volume":"59","author":"Barry C.E.","year":"2000","unstructured":"Barry C.E.; Slayden R.A.; Sampson A.E.; Lee R.E.; Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs. Biochem Pharmacol 2000,59(3),221-231","journal-title":"Biochem Pharmacol"},{"key":"ref=36","first-page":"486","volume":"1","author":"Nagarajan K.","year":"2008","unstructured":"Nagarajan K.; Mazumder A.; Ghosh L.K.; Evaluation of anti-tubercular activity directly from Versa TREK mycobottles using Wrightia tomentosa alcoholic extracts. Pharmacologyonline 2008,1,486-496","journal-title":"Pharmacologyonline"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1099\/00221287-144-9-2539","volume":"144","author":"Bardou F.","year":"1998","unstructured":"Bardou F.; Raynaud C.; Ramos C.; Lan&#xE9;elle M.A.; Lan\u0155elle G.; Mechanism of isoniazid uptake in Mycobacterium tuberculosis. Microbiology (Reading) 1998,144(9),2539-2544","journal-title":"Microbiology (Reading)"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/358591a0","volume":"358","author":"Zhang Y.","year":"1992","unstructured":"Zhang Y.; Heym B.; Allen B.; Young D.; Cole S.; The catalase\u2014peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992,358(6387),591-593","journal-title":"Nature"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"7017","DOI":"10.1074\/jbc.M808106200","volume":"284","author":"Suarez J.","year":"2009","unstructured":"Suarez J.; Ranguelova K.; Jarzecki A.A.; Manzerova J.; Krymov V.; Zhao X.; Yu S.; Metlitsky L.; Gerfen G.J.; Magliozzo R.S.; An oxyferrous heme\/protein-based radical intermediate is catalytically competent in the catalase reaction of Mycobacterium tuberculosis catalase-peroxidase (KatG). J Biol Chem 2009,284(11),7017-7029","journal-title":"J Biol Chem"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"13881","DOI":"10.1073\/pnas.2235848100","volume":"100","author":"Rawat R.","year":"2003","unstructured":"Rawat R.; Whitty A.; Tonge P.J.; The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: Adduct affinity and drug resistance. Proc Natl Acad Sci USA 2003,100(24),13881-13886","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1128\/AAC.48.8.3006-3009.2004","volume":"48","author":"Timmins G.S.","year":"2004","unstructured":"Timmins G.S.; Master S.; Rusnak F.; Deretic V.; Nitric oxide generated from isoniazid activation by KatG: source of nitric oxide and activity against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2004,48(8),3006-3009","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3390\/antibiotics3030317","volume":"3","author":"Palomino J.","year":"2014","unstructured":"Palomino J.; Martin A.; Drug Resistance Mechanisms in Mycobacterium tuberculosis. Antibiotics (Basel) 2014,3(3),317-340","journal-title":"Antibiotics (Basel)"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1146\/annurev.bi.65.070196.001243","volume":"65","author":"Blanchard J.S.","year":"1996","unstructured":"Blanchard J.S.; Molecular mechanisms of drug resistance in Mycobacterium tuberculosis. Annu Rev Biochem 1996,65(1),215-239","journal-title":"Annu Rev Biochem"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2741\/1289","volume":"9","author":"Wade M.M.","year":"2004","unstructured":"Wade M.M.; Zhang Y.; Mechanisms of drug resistance in mycobacterium tuberculosis. Front Biosci 2004,9(1-3),975-994","journal-title":"Front Biosci"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.2174\/09298673113209990166","volume":"20","author":"Palomino J.","year":"2013","unstructured":"Palomino J.; Martin A.; Tuberculosis clinical trial update and the current anti-tuberculosis drug portfolio. Curr Med Chem 2013,20(30),3785-3796","journal-title":"Curr Med Chem"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"7527","DOI":"10.1128\/AAC.03169-14","volume":"58","author":"Piccaro G.","year":"2014","unstructured":"Piccaro G.; Pietraforte D.; Giannoni F.; Mustazzolu A.; Fattorini L.; Rifampin induces hydroxyl radical formation in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014,58(12),7527-7533","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"8020","DOI":"10.1128\/JB.187.23.8020-8025.2005","volume":"187","author":"Miku\u0161ov&#xE1; K.","year":"2005","unstructured":"Miku\u0161ov&#xE1; K.; Huang H.; Yagi T.; Holsters M.; Vereecke D.; D\u2019Haeze W.; Scherman M.S.; Brennan P.J.; McNeil M.R.; Crick D.C.; Decaprenylphosphoryl arabinofuranose, the donor of the D-arabinofuranosyl residues of mycobacterial arabinan, is formed via a two-step epimerization of decaprenylphosphoryl ribose. J Bacteriol 2005,187(23),8020-8025","journal-title":"J Bacteriol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1128\/AAC.00453-10","volume":"54","author":"Wang F.","year":"2010","unstructured":"Wang F.; Jain P.; Gulten G.; Liu Z.; Feng Y.; Ganesula K.; Motiwala A.S.; Ioerger T.R.; Alland D.; Vilch&#xE8;ze C.; Jacobs W.R.; Sacchettini J.C.; Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid. Antimicrob Agents Chemother 2010,54(9),3776-3782","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=49","first-page":"1320","volume":"13","author":"Zhang Y.","year":"2009","unstructured":"Zhang Y.; Yew W.W.; Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009,13(11),1320-1330","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1128\/AAC.39.11.2484","volume":"39","author":"Mikusov&#xE1; K.","year":"1995","unstructured":"Mikusov&#xE1; K.; Slayden R.A.; Besra G.S.; Brennan P.J.; Biogenesis of the mycobacterial cell wall and the site of action of ethambutol. Antimicrob Agents Chemother 1995,39(11),2484-2489","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/nm0696-662","volume":"2","author":"Scorpio A.","year":"1996","unstructured":"Scorpio A.; Zhang Y.; Mutations in pncA, a gene encoding pyrazinamidase\/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 1996,2(6),662-667","journal-title":"Nat Med"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/jac\/dkg446","volume":"52","author":"Zhang Y.","year":"2003","unstructured":"Zhang Y.; Wade M.M.; Scorpio A.; Zhang H.; Sun Z.; Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother 2003,52(5),790-795","journal-title":"J Antimicrob Chemother"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1093\/jac\/dkr284","volume":"66","author":"Shi D.","year":"2011","unstructured":"Shi D.; Li L.; Zhao Y.; Jia Q.; Li H.; Coulter C.; Jin Q.; Zhu G.; Characteristics of embB mutations in multidrug-resistant Mycobacterium tuberculosis isolates in Henan, China. J Antimicrob Chemother 2011,66(10),2240-2247","journal-title":"J Antimicrob Chemother"},{"key":"ref=54","first-page":"e58","volume":"3","author":"Shi W.","year":"2014","unstructured":"Shi W.; Chen J.; Feng J.; Cui P.; Zhang S.; Weng X.; Zhang W.; Zhang Y.; Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis. Emerg Microbes Infect 2014,3(8),e58","journal-title":"Emerg Microbes Infect"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/emi.2017.1","volume":"6","author":"Zhang S.","year":"2017","unstructured":"Zhang S.; Chen J.; Shi W.; Cui P.; Zhang J.; Cho S.; Zhang W.; Zhang Y.; Mutation in clpC1 encoding an ATP-dependent ATPase involved in protein degradation is associated with pyrazinamide resistance in Mycobacterium tuberculosis. Emerg Microbes Infect 2017,6(1),1-2","journal-title":"Emerg Microbes Infect"},{"key":"ref=56","first-page":"9949","author":"Heifets L.","year":"2005","unstructured":"Heifets L.; Desmond E.; Clinical Mycobacteriology Laboratory. Tuberculosis and the tubercle bacillus 2005,9949-9970","journal-title":"Tuberculosis and the tubercle bacillus"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"96","DOI":"10.2174\/157016461202150903113053","volume":"12","author":"Sharma D.","year":"2015","unstructured":"Sharma D.; Lata M.; Faheem M.; Khan A.; Joshi B.; Venkatesan K.; Shukla S.; Bisht D.; Cloning, expression and correlation of Rv0148 to amikacin and kanamycin resistance. Curr Proteomics 2015,12(2),96-100","journal-title":"Curr Proteomics"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1126\/science.1228980","volume":"339","author":"Chakraborty S.","year":"2013","unstructured":"Chakraborty S.; Gruber T.; Barry C.E.; Boshoff H.I.; Rhee K.Y.; Para-aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis. Science 2013,339(6115),88-91","journal-title":"Science"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"23447","DOI":"10.1074\/jbc.M113.475798","volume":"288","author":"Zheng J.","year":"2013","unstructured":"Zheng J.; Rubin E.J.; Bifani P.; Mathys V.; Lim V.; Au M.; Jang J.; Nam J.; Dick T.; Walker J.R.; Pethe K.; Camacho L.R.; para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis. J Biol Chem 2013,288(32),23447-23456","journal-title":"J Biol Chem"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1093\/nar\/gkr1113","volume":"40","author":"Carette X.","year":"2012","unstructured":"Carette X.; Blondiaux N.; Willery E.; Hoos S.; Lecat-Guillet N.; Lens Z.; Wohlk&#xF6;nig A.; Wintjens R.; Soror S.H.; Fr&#xE9;nois F.; Diri&#xE9; B.; Villeret V.; England P.; Lippens G.; Deprez B.; Locht C.; Willand N.; Baulard A.R.; Structural activation of the transcriptional repressor EthR from Mycobacterium tuberculosis by single amino acid change mimicking natural and synthetic ligands. Nucleic Acids Res 2012,40(7),3018-3030","journal-title":"Nucleic Acids Res"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1128\/AAC.36.6.1316","volume":"36","author":"Qu&#xE9;mard A.","year":"1992","unstructured":"Qu&#xE9;mard A.; Lan&#xE9;elle G.; Lacave C.; Mycolic acid synthesis: a target for ethionamide in mycobacteria? Antimicrob Agents Chemother 1992,36(6),1316-1321","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"12824","DOI":"10.1074\/jbc.M110751200","volume":"277","author":"Vannelli T.A.","year":"2002","unstructured":"Vannelli T.A.; Dykman A.; Ortiz de Montellano P.R.; The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase. J Biol Chem 2002,277(15),12824-12829","journal-title":"J Biol Chem"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.chembiol.2016.05.011","volume":"23","author":"Grant S.S.","year":"2016","unstructured":"Grant S.S.; Wellington S.; Kawate T.; Desjardins C.A.; Silvis M.R.; Wivagg C.; Thompson M.; Gordon K.; Kazyanskaya E.; Nietupski R.; Haseley N.; Iwase N.; Earl A.M.; Fitzgerald M.; Hung D.T.; Baeyer-villiger monooxygenases EthA and MymA are required for activation of replicating and non-replicating mycobacterium tuberculosis inhibitors. Cell Chem Biol 2016,23(6),666-677","journal-title":"Cell Chem Biol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.drudis.2016.09.006","volume":"22","author":"Mori G.","year":"2017","unstructured":"Mori G.; Chiarelli L.R.; Riccardi G.; Pasca M.R.; New prodrugs against tuberculosis. Drug Discov Today 2017,22(3),519-525","journal-title":"Drug Discov Today"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1146\/annurev.pharmtox.45.120403.100120","volume":"45","author":"Zhang Y.","year":"2005","unstructured":"Zhang Y.; The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol 2005,45(1),529-564","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"7145","DOI":"10.1021\/bi400839f","volume":"52","author":"Prosser G.A.","year":"2013","unstructured":"Prosser G.A.; de Carvalho L.P.S.; Reinterpreting the mechanism of inhibition of Mycobacterium tuberculosis D-alanine:D-alanine ligase by D-cycloserine. Biochemistry 2013,52(40),7145-7149","journal-title":"Biochemistry"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.5588\/ijtld.15.0389","volume":"19","author":"Zhang Y.","year":"2015","unstructured":"Zhang Y.; Yew W-W.; Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015. Int J Tuberc Lung Dis 2015,19(11),1276-1289","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref=68","first-page":"E1","volume":"32","author":"Pallo-Zimmerman L.M.","year":"2010","unstructured":"Pallo-Zimmerman L.M.; Byron J.K.; Graves T.K.; Fluoroquinolones: then and now. Compend Contin Educ Vet 2010,32(7),E1-E9","journal-title":"Compend Contin Educ Vet"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1128\/AAC.40.7.1594","volume":"40","author":"Drlica K.","year":"1996","unstructured":"Drlica K.; Xu C.; Wang J.Y.; Burger R.M.; Malik M.; Fluoroquinolone action in mycobacteria: similarity with effects in Escherichia coli and detection by cell lysate viscosity. Antimicrob Agents Chemother 1996,40(7),1594-1599","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1128\/AAC.48.4.1281-1288.2004","volume":"48","author":"Aubry A.","year":"2004","unstructured":"Aubry A.; Pan X.S.; Fisher L.M.; Jarlier V.; Cambau E.; Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. Antimicrob Agents Chemother 2004,48(4),1281-1288","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1128\/AAC.42.5.1295","volume":"42","author":"Alangaden G.J.","year":"1998","unstructured":"Alangaden G.J.; Kreiswirth B.N.; Aouad A.; Khetarpal M.; Igno F.R.; Moghazeh S.L.; Manavathu E.K.; Lerner S.A.; Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998,42(5),1295-1297","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1128\/JCM.36.5.1220-1225.1998","volume":"36","author":"Suzuki Y.","year":"1998","unstructured":"Suzuki Y.; Katsukawa C.; Tamaru A.; Abe C.; Makino M.; Mizuguchi Y.; Taniguchi H.; Detection of kanamycin-resistant Mycobacterium tuberculosis by identifying mutations in the 16S rRNA gene. J Clin Microbiol 1998,36(5),1220-1225","journal-title":"J Clin Microbiol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/nsmb.1755","volume":"17","author":"Stanley R.E.","year":"2010","unstructured":"Stanley R.E.; Blaha G.; Grodzicki R.L.; Strickler M.D.; Steitz T.A.; The structures of the anti-tuberculosis antibiotics viomycin and capreomycin bound to the 70S ribosome. Nat Struct Mol Biol 2010,17(3),289-293","journal-title":"Nat Struct Mol Biol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1128\/AAC.01182-08","volume":"53","author":"Williams K.N.","year":"2009","unstructured":"Williams K.N.; Stover C.K.; Zhu T.; Tasneen R.; Tyagi S.; Grosset J.H.; Nuermberger E.; Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother 2009,53(4),1314-1319","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1086\/313954","volume":"31","author":"Bartlett J.G.","year":"2000","unstructured":"Bartlett J.G.; Dowell S.F.; Mandell L.A.; File T.M.; Musher D.M.; Fine M.J.; Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000,31(2),347-382","journal-title":"Clin Infect Dis"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S0140-6736(87)91205-0","volume":"330","author":"Neu H.","year":"1987","unstructured":"Neu H.; Clinical use of the quinolones. Lancet 1987,330(8571),1319-1322","journal-title":"Lancet"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/0962-8479(92)90044-K","volume":"73","author":"Grosset J.H.","year":"1992","unstructured":"Grosset J.H.; Treatment of tuberculosis in HIV infection. Tuber Lung Dis 1992,73(6),378-383","journal-title":"Tuber Lung Dis"},{"key":"ref=78","first-page":"352","volume":"131","author":"Tsukamura M.","year":"1985","unstructured":"Tsukamura M.; Nakamura E.; Yoshii S.; Amano H.; Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. Am Rev Respir Dis 1985,131(3),352-356","journal-title":"Am Rev Respir Dis"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1128\/AAC.39.8.1700","volume":"39","author":"Alangaden G.J.","year":"1995","unstructured":"Alangaden G.J.; Manavathu E.K.; Vakulenko S.B.; Zvonok N.M.; Lerner S.A.; Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients. Antimicrob Agents Chemother 1995,39(8),1700-1703","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S1473-3099(03)00671-6","volume":"3","author":"Ginsburg A.S.","year":"2003","unstructured":"Ginsburg A.S.; Grosset J.H.; Bishai W.R.; Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003,3(7),432-442","journal-title":"Lancet Infect Dis"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1128\/AAC.44.9.2567-2568.2000","volume":"44","author":"Ruiz-Serrano M.J.","year":"2000","unstructured":"Ruiz-Serrano M.J.; Alcal&#xE1; L.; Mart&#xED;nez L.; D&#xED;az M.; Mar&#xED;n M.; Gonz&#xE1;lez-Abad M.J.; Bouza E.; In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs. Antimicrob Agents Chemother 2000,44(9),2567-2568","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1086\/379328","volume":"37","author":"Ginsburg A.S.","year":"2003","unstructured":"Ginsburg A.S.; Hooper N.; Parrish N.; Dooley K.E.; Dorman S.E.; Booth J.; Diener-West M.; Merz W.G.; Bishai W.R.; Sterling T.R.; Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis 2003,37(11),1448-1452","journal-title":"Clin Infect Dis"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1086\/516116","volume":"25","author":"Alangaden G.J.","year":"1997","unstructured":"Alangaden G.J.; Lerner S.A.; The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin Infect Dis 1997,25(5),1213-1221","journal-title":"Clin Infect Dis"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0924-8579(00)00337-X","volume":"17","author":"Rodr&#xED;guez J.C.","year":"2001","unstructured":"Rodr&#xED;guez J.C.; Ruiz M.; Climent A.; Royo G.; In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis. Int J Antimicrob Agents 2001,17(3),229-231","journal-title":"Int J Antimicrob Agents"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1179\/joc.2005.17.2.169","volume":"17","author":"Sulochana S.","year":"2005","unstructured":"Sulochana S.; Rahman F.; Paramasivan C.N.; In vitro activity of fluoroquinolones against Mycobacterium tuberculosis. J Chemother 2005,17(2),169-173","journal-title":"J Chemother"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1093\/jac\/25.5.880","volume":"25","author":"Yew W.W.","year":"1990","unstructured":"Yew W.W.; Kwan S.Y.L.; Ma W.K.; Lui K.S.; Suen H.C.; Ofloxacin therapy of Mycobaeterium fortuitum infection: further experience. J Antimicrob Chemother 1990,25(5),880-881","journal-title":"J Antimicrob Chemother"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1128\/AAC.46.4.1022-1025.2002","volume":"46","author":"Alvirez-Freites E.J.","year":"2002","unstructured":"Alvirez-Freites E.J.; Carter J.L.; Cynamon M.H.; In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002,46(4),1022-1025","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1128\/AAC.49.2.627-631.2005","volume":"49","author":"Paramasivan C.N.","year":"2005","unstructured":"Paramasivan C.N.; Sulochana S.; Kubendiran G.; Venkatesan P.; Mitchison D.A.; Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005,49(2),627-631","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1128\/AAC.47.2.653-657.2003","volume":"47","author":"Hu Y.","year":"2003","unstructured":"Hu Y.; Coates A.R.M.; Mitchison D.A.; Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003,47(2),653-657","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1128\/AAC.49.6.2294-2301.2005","volume":"49","author":"Lenaerts A.J.","year":"2005","unstructured":"Lenaerts A.J.; Gruppo V.; Marietta K.S.; Johnson C.M.; Driscoll D.K.; Tompkins N.M.; Rose J.D.; Reynolds R.C.; Orme I.M.; Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother 2005,49(6),2294-2301","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1128\/AAC.47.8.2442-2444.2003","volume":"47","author":"Cynamon M.H.","year":"2003","unstructured":"Cynamon M.H.; Sklaney M.; Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis. Antimicrob Agents Chemother 2003,47(8),2442-2444","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1128\/AAC.43.1.85","volume":"43","author":"Miyazaki E.","year":"1999","unstructured":"Miyazaki E.; Miyazaki M.; Chen J.M.; Chaisson R.E.; Bishai W.R.; Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother 1999,43(1),85-89","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1164\/rccm.200310-1380OC","volume":"169","author":"Nuermberger E.L.","year":"2004","unstructured":"Nuermberger E.L.; Yoshimatsu T.; Tyagi S.; O\u2019Brien R.J.; Vernon A.N.; Chaisson R.E.; Bishai W.R.; Grosset J.H.; Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004,169(3),421-426","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1164\/rccm.200407-885OC","volume":"170","author":"Nuermberger E.L.","year":"2004","unstructured":"Nuermberger E.L.; Yoshimatsu T.; Tyagi S.; Williams K.; Rosenthal I.; O\u2019Brien R.J.; Vernon A.A.; Chaisson R.E.; Bishai W.R.; Grosset J.H.; Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 2004,170(10),1131-1134","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1128\/AAC.36.3.548","volume":"36","author":"Grosset J.","year":"1992","unstructured":"Grosset J.; Truffot-Pernot C.; Lacroix C.; Ji B.; Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother 1992,36(3),548-551","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1128\/AAC.49.9.3977-3979.2005","volume":"49","author":"Ginsburg A.S.","year":"2005","unstructured":"Ginsburg A.S.; Sun R.; Calamita H.; Scott C.P.; Bishai W.R.; Grosset J.H.; Emergence of fluoroquinolone resistance in Mycobacterium tuberculosis during continuously dosed moxifloxacin monotherapy in a mouse model. Antimicrob Agents Chemother 2005,49(9),3977-3979","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1164\/rccm.200603-360OC","volume":"174","author":"Burman W.J.","year":"2006","unstructured":"Burman W.J.; Goldberg S.; Johnson J.L.; Muzanye G.; Engle M.; Mosher A.W.; Choudhri S.; Daley C.L.; Munsiff S.S.; Zhao Z.; Vernon A.; Chaisson R.E.; Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006,174(3),331-338","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1128\/AAC.42.10.2674","volume":"42","author":"Oleksijew A.","year":"1998","unstructured":"Oleksijew A.; Meulbroek J.; Ewing P.; Jarvis K.; Mitten M.; Paige L.; Tovcimak A.; Nukkula M.; Chu D.; Alder J.D.; In vivo efficacy of ABT-255 against drug-sensitive and -resistant Mycobacterium tuberculosis strains. Antimicrob Agents Chemother 1998,42(10),2674-2677","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1128\/AAC.39.4.964","volume":"39","author":"Flamm R.K.","year":"1995","unstructured":"Flamm R.K.; Vojtko C.; Chu D.T.; Li Q.; Beyer J.; Hensey D.; Ramer N.; Clement J.J.; Tanaka S.K.; In vitro evaluation of ABT-719, a novel DNA gyrase inhibitor. Antimicrob Agents Chemother 1995,39(4),964-970","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1128\/AAC.39.10.2295","volume":"39","author":"Hirata T.","year":"1995","unstructured":"Hirata T.; Saito H.; Tomioka H.; Sato K.; Jidoi J.; Hosoe K.; Hidaka T.; In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995,39(10),2295-2303","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"S288","DOI":"10.1086\/313876","volume":"30","author":"Shoen C.M.","year":"2000","unstructured":"Shoen C.M.; DeStefano M.S.; Cynamon M.H.; Durable cure for tuberculosis: rifalazil in combination with isoniazid in a murine model of Mycobacterium tuberculosis infection. Clin Infect Dis 2000,30(3)(Suppl. 3),S288-S290","journal-title":"Clin Infect Dis"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1128\/AAC.40.11.2655","volume":"40","author":"Moghazeh S.L.","year":"1996","unstructured":"Moghazeh S.L.; Pan X.; Arain T.; Stover C.K.; Musser J.M.; Kreiswirth B.N.; Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob Agents Chemother 1996,40(11),2655-2657","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1126\/science.1106753","volume":"307","author":"Andries K.","year":"2005","unstructured":"Andries K.; Verhasselt P.; Guillemont J.; G&#xF6;hlmann H.W.H.; Neefs J-M.; Winkler H.; Van Gestel J.; Timmerman P.; Zhu M.; Lee E.; Williams P.; de Chaffoy D.; Huitric E.; Hoffner S.; Cambau E.; Truffot-Pernot C.; Lounis N.; Jarlier V.; A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005,307(5707),223-227","journal-title":"Science"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nchembio884","volume":"3","author":"Koul A.","year":"2007","unstructured":"Koul A.; Dendouga N.; Vergauwen K.; Molenberghs B.; Vranckx L.; Willebrords R.; Ristic Z.; Lill H.; Dorange I.; Guillemont J.; Bald D.; Andries K.; Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol 2007,3(6),323-324","journal-title":"Nat Chem Biol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"e466","DOI":"10.1371\/journal.pmed.0030466","volume":"3","author":"Matsumoto M.","year":"2006","unstructured":"Matsumoto M.; Hashizume H.; Tomishige T.; Kawasaki M.; Tsubouchi H.; Sasaki H.; Shimokawa Y.; Komatsu M.; OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006,3(11),e466","journal-title":"PLoS Med"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1742-4658.2011.08404.x","volume":"279","author":"Gurumurthy M.","year":"2012","unstructured":"Gurumurthy M.; Tathagate M.; Cynthia D.S.; Singh R.; Niyomrattanakit P.; Tay J.A.; Nayyar A.; Lee Y.S.; Cherian J.; Boshoff H.I.; Dick T.; Barry C.E.; Manjunatha U.H.; Substrate specificity of the deazaflavin-dependent nitroreductase from tuberculosis\u2003Mycobacterium responsible for the bioreductive activation of bicyclic nitroimidazoles. FEBS J 2012,279,113-125","journal-title":"FEBS J"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/35016103","volume":"405","author":"Stover C.K.","year":"2000","unstructured":"Stover C.K.; Warrener P.; VanDevanter D.R.; Sherman D.R.; Arain T.M.; Langhorne M.H.; Anderson S.W.; Towell J.A.; Yuan Y.; McMurray D.N.; Kreiswirth B.N.; Barry C.E.; Baker W.R.; A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000,405(6789),962-966","journal-title":"Nature"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1073\/pnas.0508392103","volume":"103","author":"Manjunatha U.H.","year":"2006","unstructured":"Manjunatha U.H.; Boshoff H.; Dowd C.S.; Zhang L.; Albert T.J.; Norton J.E.; Daniels L.; Dick T.; Pang S.S.; Barry C.E.; Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci 2006,103(2),431-436","journal-title":"Proc Natl Acad Sci"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"11945","DOI":"10.1073\/pnas.0711697105","volume":"105","author":"Rao S.P.S.","year":"2008","unstructured":"Rao S.P.S.; Alonso S.; Rand L.; Dick T.; Pethe K.; The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc Natl Acad Sci 2008,105(33),11945-11950","journal-title":"Proc Natl Acad Sci"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1126\/science.1164571","volume":"322","author":"Singh R.","year":"2008","unstructured":"Singh R.; Manjunatha U.; Boshoff H.I.M.; Ha Y.H.; Niyomrattanakit P.; Ledwidge R.; Dowd C.S.; Lee I.Y.; Kim P.; Zhang L.; Kang S.; Keller T.H.; Jiricek J.; Barry C.E.; PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release. Science 2008,322(5906),1392-1395","journal-title":"Science"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1128\/AAC.05708-11","volume":"56","author":"Tahlan K.","year":"2012","unstructured":"Tahlan K.; Wilson R.; Kastrinsky D.B.; Arora K.; Nair V.; Fischer E.; Barnes S.W.; Walker J.R.; Alland D.; Barry C.E.; Boshoff H.I.; SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2012,56(4),1797-1809","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"e90868","DOI":"10.1371\/journal.pone.0090868","volume":"9","author":"Bantubani N.","year":"2014","unstructured":"Bantubani N.; Kabera G.; Connolly C.; Rustomjee R.; Reddy T.; Cohen T.; Pym A.S.; High rates of potentially infectious tuberculosis and multidrug-resistant tuberculosis (MDR-TB) among hospital inpatients in KwaZulu Natal, South Africa indicate risk of nosocomial transmission. PLoS One 2014,9(3),e90868","journal-title":"PLoS One"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"e0119628","DOI":"10.1371\/journal.pone.0119628","volume":"10","author":"Seifert M.","year":"2015","unstructured":"Seifert M.; Catanzaro D.; Catanzaro A.; Rodwell T.C.; Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review. PLoS One 2015,10(3),e0119628","journal-title":"PLoS One"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jiac.2015.12.009","volume":"22","author":"Aye K.S.","year":"2016","unstructured":"Aye K.S.; Nakajima C.; Yamaguchi T.; Win M.M.; Shwe M.M.; Win A.A.; Lwin T.; Nyunt W.W.; Ti T.; Suzuki Y.; Genotypic characterization of multi-drug-resistant Mycobacterium tuberculosis isolates in Myanmar. J Infect Chemother 2016,22(3),174-179","journal-title":"J Infect Chemother"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.tube.2016.02.004","volume":"98","author":"Datta G.","year":"2016","unstructured":"Datta G.; Nieto L.M.; Davidson R.M.; Mehaffy C.; Pederson C.; Dobos K.M.; Strong M.; Longitudinal whole genome analysis of pre and post drug treatment Mycobacterium tuberculosis isolates reveals progressive steps to drug resistance. Tuberculosis (Edinb) 2016,98,50-55","journal-title":"Tuberculosis (Edinb)"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1128\/AAC.06460-11","volume":"56","author":"Fenner L.","year":"2012","unstructured":"Fenner L.; Egger M.; Bodmer T.; Altpeter E.; Zwahlen M.; Jaton K.; Pfyffer G.E.; Borrell S.; Dubuis O.; Bruderer T.; Siegrist H.H.; Furrer H.; Calmy A.; Fehr J.; Stalder J.M.; Ninet B.; B&#xF6;ttger E.C.; Gagneux S.; Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2012,56(6),3047-3053","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=117","first-page":"344","volume":"15","author":"M&#xFC;ller B.","year":"2011","unstructured":"M&#xFC;ller B.; Streicher E.M.; Hoek K.G.; Tait M.; Trollip A.; Bosman M.E.; Coetzee G.J.; Chabula-Nxiweni E.M.; Hoosain E.; Gey van Pittius N.C.; Victor T.C.; van Helden P.D.; Warren R.M.; Hanekom M.; Coetzee G.; Trollip A.; Hayes C.; Bosman M.E.; van Pittius N.C.G.; Victor T.C.; van Helden P.D.; Warren R.M.; inhA promoter mutations: a gateway to extensively drug-resistant tuberculosis in South Africa? Int J Tuberc Lung Dis 2011,15(3),344-351","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1093\/jac\/dkt090","volume":"68","author":"Machado D.","year":"2013","unstructured":"Machado D.; Perdig&#xE3;o J.; Ramos J.; Couto I.; Portugal I.; Ritter C.; Boettger E.C.; Viveiros M.; High-level resistance to isoniazid and ethionamide in multidrug-resistant Mycobacterium tuberculosis of the Lisboa family is associated with inhA double mutations. J Antimicrob Chemother 2013,68(8),1728-1732","journal-title":"J Antimicrob Chemother"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/nm1466","volume":"12","author":"Vilch&#xE8;ze C.","year":"2006","unstructured":"Vilch&#xE8;ze C.; Wang F.; Arai M.; Hazb&#xF3;n M.H.; Colangeli R.; Kremer L.; Weisbrod T.R.; Alland D.; Sacchettini J.C.; Jacobs W.R.; Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat Med 2006,12(9),1027-1029","journal-title":"Nat Med"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"e90569","DOI":"10.1371\/journal.pone.0090569","volume":"9","author":"Ocheretina O.","year":"2014","unstructured":"Ocheretina O.; Escuyer V.E.; Mabou M.M.; Royal-Mardi G.; Collins S.; Vilbrun S.C.; Pape J.W.; Fitzgerald D.W.; Correlation between genotypic and phenotypic testing for resistance to rifampin in Mycobacterium tuberculosis clinical isolates in Haiti: investigation of cases with discrepant susceptibility results. PLoS One 2014,9(3),e90569","journal-title":"PLoS One"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jiph.2015.05.003","volume":"8","author":"Thirumurugan R.","year":"2015","unstructured":"Thirumurugan R.; Kathirvel M.; Vallayyachari K.; Surendar K.; Samrot A.V.; Muthaiah M.; Molecular analysis of rpoB gene mutations in rifampicin resistant Mycobacterium tuberculosis isolates by multiple allele specific polymerase chain reaction in Puducherry, South India. J Infect Public Health 2015,8(6),619-625","journal-title":"J Infect Public Health"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1186\/1471-2334-14-481","volume":"14","author":"Mboowa G.","year":"2014","unstructured":"Mboowa G.; Namaganda C.; Ssengooba W.; Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert&#xAE;MTB\/RIF in Kampala, Uganda: a retrospective study. BMC Infect Dis 2014,14(1),481","journal-title":"BMC Infect Dis"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/ng.1038","volume":"44","author":"Comas I.","year":"2012","unstructured":"Comas I.; Borrell S.; Roetzer A.; Rose G.; Malla B.; Kato-Maeda M.; Galagan J.; Niemann S.; Gagneux S.; Whole-genome sequencing of rifampicin-resistant M. tuberculosis strains identifies compensatory mutations in RNA polymerase. Nat Genet 2012,44,106-110","journal-title":"Nat Genet"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1093\/jac\/dkt224","volume":"68","author":"Brandis G.","year":"2013","unstructured":"Brandis G.; Hughes D.; Genetic characterization of compensatory evolution in strains carrying rpoB Ser531Leu, the rifampicin resistance mutation most frequently found in clinical isolates. J Antimicrob Chemother 2013,68(11),2493-2497","journal-title":"J Antimicrob Chemother"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/951706","volume":"2015","author":"Xu Y.","year":"2015","unstructured":"Xu Y.; Jia H.; Huang H.; Sun Z.; Zhang Z.; Mutations found in embCAB, embR, and ubiA genes of ethambutol-sensitive and -resistant Mycobacterium tuberculosis clinical isolates from China. BioMed Res Int 2015,2015,1-8","journal-title":"BioMed Res Int"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1128\/AAC.01516-06","volume":"51","author":"Shen X.","year":"2007","unstructured":"Shen X.; Shen G.; Wu J.; Gui X.; Li X.; Mei J.; DeRiemer K.; Gao Q.; Association between embB codon 306 mutations and drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2007,51(7),2618-2620","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ijantimicag.2008.09.021","volume":"33","author":"Perdig&#xE3;o J.","year":"2009","unstructured":"Perdig&#xE3;o J.; Macedo R.; Ribeiro A.; Brum L.; Portugal I.; Genetic characterisation of the ethambutol resistance-determining region in Mycobacterium tuberculosis: prevalence and significance of embB306 mutations. Int J Antimicrob Agents 2009,33(4),334-338","journal-title":"Int J Antimicrob Agents"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1128\/JCM.02713-13","volume":"52","author":"Zhang Z.","year":"2014","unstructured":"Zhang Z.; Wang Y.; Pang Y.; Kam K.M.; Ethambutol resistance as determined by broth dilution method correlates better than sequencing results with embB mutations in multidrug-resistant Mycobacterium tuberculosis isolates. J Clin Microbiol 2014,52(2),638-641","journal-title":"J Clin Microbiol"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"4800","DOI":"10.1128\/AAC.00150-15","volume":"59","author":"Brossier F.","year":"2015","unstructured":"Brossier F.; Sougakoff W.; Bernard C.; Petrou M.; Adeyema K.; Pham A.; Amy de la Breteque D.; Vallet M.; Jarlier V.; Sola C.; Veziris N.; Molecular analysis of the embCAB locus and embR gene involved in ethambutol resistance in clinical isolates of Mycobacterium Tuberculosis in France. Antimicrob Agents Chemother 2015,59(8),4800-4808","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/916780","volume":"2015","author":"Tye G.J.","year":"2015","unstructured":"Tye G.J.; Lew M.H.; Choong Y.S.; Lim T.S.; Sarmiento M.E.; Acosta A.; Norazmi M.N.; Vaccines for TB: Lessons from the Past Translating into Future Potentials. J Immunol Res 2015,2015,1-9","journal-title":"J Immunol Res"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1126\/science.1208813","volume":"333","author":"Shi W.","year":"2011","unstructured":"Shi W.; Zhang X.; Jiang X.; Yuan H.; Lee J.S.; Barry C.E.; Wang H.; Zhang W.; Zhang Y.; Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 2011,333(6049),1630-1632","journal-title":"Science"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1038\/ng.2743","volume":"45","author":"Safi H.","year":"2013","unstructured":"Safi H.; Lingaraju S.; Amin A.; Kim S.; Jones M.; Holmes M.; McNeil M.; Peterson S.N.; Chatterjee D.; Fleischmann R.; Alland D.; Evolution of high-level ethambutol-resistant tuberculosis through interacting mutations in decaprenylphosphoryl-&#x3B2;-D-arabinose biosynthetic and utilization pathway genes. Nat Genet 2013,45(10),1190-1197","journal-title":"Nat Genet"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"5889","DOI":"10.1002\/anie.201101740","volume":"50","author":"Schmitt E.K.","year":"2011","unstructured":"Schmitt E.K.; Riwanto M.; Sambandamurthy V.; Roggo S.; Miault C.; Zwingelstein C.; Krastel P.; Noble C.; Beer D.; Rao S.P.S.; Au M.; Niyomrattanakit P.; Lim V.; Zheng J.; Jeffery D.; Pethe K.; Camacho L.R.; The natural product cyclomarin kills Mycobacterium tuberculosis by targeting the ClpC1 subunit of the caseinolytic protease. Angew Chem Int Ed 2011,50(26),5889-5891","journal-title":"Angew Chem Int Ed"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"1016.e1","DOI":"10.1016\/j.cmi.2017.12.012","volume":"24","author":"Liu W.","year":"2018","unstructured":"Liu W.; Chen J.; Shen Y.; Jin J.; Wu J.; Sun F.; Wu Y.; Xie L.; Zhang Y.; Zhang W.; Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis clinical isolates in Hangzhou, China. Clin Microbiol Infect 2018,24(9),1016.e1-1016.e5","journal-title":"Clin Microbiol Infect"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1128\/AAC.00110-08","volume":"52","author":"Jur&#xE9;en P.","year":"2008","unstructured":"Jur&#xE9;en P.; Werngren J.; Toro J.C.; Hoffner S.; Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2008,52(5),1852-1854","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/scipharm86020015","volume":"86","author":"Kahbazi M.","year":"2018","unstructured":"Kahbazi M.; Sarmadian H.; Ahmadi A.; Didgar F.; Sadrnia M.; Poolad T.; Arjomandzadegan M.; Novel mutations in pncA gene of pyrazinamide resistant clinical isolates of Mycobacterium tuberculosis. Sci Pharm 2018,86(2),15","journal-title":"Sci Pharm"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1365-2958.1993.tb01253.x","volume":"9","author":"Finken M.","year":"1993","unstructured":"Finken M.; Kirschner P.; Meier A.; Wrede A.; B&#xF6;ttger E.C.; Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot. Mol Microbiol 1993,9(6),1239-1246","journal-title":"Mol Microbiol"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"O278","DOI":"10.1111\/1469-0691.12392","volume":"20","author":"Perdig&#xE3;o J.","year":"2014","unstructured":"Perdig&#xE3;o J.; Macedo R.; Machado D.; Silva C.; Jord&#xE3;o L.; Couto I.; Viveiros M.; Portugal I.; GidB mutation as a phylogenetic marker for Q1 cluster Mycobacterium tuberculosis isolates and intermediate-level streptomycin resistance determinant in Lisbon, Portugal. Clin Microbiol Infect 2014,20(5),O278-O284","journal-title":"Clin Microbiol Infect"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1128\/AAC.40.4.1024","volume":"40","author":"Sreevatsan S.","year":"1996","unstructured":"Sreevatsan S.; Pan X.; Stockbauer K.E.; Williams D.L.; Kreiswirth B.N.; Musser J.M.; Characterization of rpsL and rrs mutations in streptomycin-resistant Mycobacterium tuberculosis isolates from diverse geographic localities. Antimicrob Agents Chemother 1996,40(4),1024-1026","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"5046","DOI":"10.1128\/jb.179.16.5046-5055.1997","volume":"179","author":"C&#xE1;ceres N.E.","year":"1997","unstructured":"C&#xE1;ceres N.E.; Harris N.B.; Wellehan J.F.; Feng Z.; Kapur V.; Barletta R.G.; Overexpression of the D-alanine racemase gene confers resistance to D-cycloserine in Mycobacterium smegmatis. J Bacteriol 1997,179(16),5046-5055","journal-title":"J Bacteriol"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1128\/AAC.06272-11","volume":"56","author":"Pantel A.","year":"2012","unstructured":"Pantel A.; Petrella S.; Veziris N.; Brossier F.; Bastian S.; Jarlier V.; Mayer C.; Aubry A.; Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis. Antimicrob Agents Chemother 2012,56(4),1990-1996","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1099\/jmm.0.046821-0","volume":"62","author":"Nosova E.Y.","year":"2013","unstructured":"Nosova E.Y.; Bukatina A.A.; Isaeva Y.D.; Makarova M.V.; Galkina K.Y.; Moroz A.M.; Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin. J Med Microbiol 2013,62(1),108-113","journal-title":"J Med Microbiol"},{"key":"ref=143","first-page":"e19","volume":"3","author":"Li J.","year":"2014","unstructured":"Li J.; Gao X.; Luo T.; Wu J.; Sun G.; Liu Q.; Jiang Y.; Zhang Y.; Mei J.; Gao Q.; Association of gyrA\/B mutations and resistance levels to fluoroquinolones in clinical isolates of Mycobacterium tuberculosis. Emerg Microbes Infect 2014,3(3),e19","journal-title":"Emerg Microbes Infect"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/1471-2334-11-78","volume":"11","author":"Cui Z.","year":"2011","unstructured":"Cui Z.; Wang J.; Lu J.; Huang X.; Hu Z.; Association of mutation patterns in gyrA\/B genes and ofloxacin resistance levels in Mycobacterium tuberculosisisolates from East China in 2009. BMC Infect Dis 2011,11(1),78","journal-title":"BMC Infect Dis"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.ijantimicag.2012.02.015","volume":"39","author":"Long Q.","year":"2012","unstructured":"Long Q.; Li W.; Du Q.; Fu Y.; Liang Q.; Huang H.; Xie J.; gyrA\/B fluoroquinolone resistance allele profiles amongst Mycobacterium tuberculosis isolates from mainland China. Int J Antimicrob Agents 2012,39(6),486-489","journal-title":"Int J Antimicrob Agents"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1128\/JCM.00113-11","volume":"49","author":"Ajbani K.","year":"2011","unstructured":"Ajbani K.; Rodrigues C.; Shenai S.; Mehta A.; Mutation detection and accurate diagnosis of extensively drug-resistant tuberculosis: report from a tertiary care center in India. J Clin Microbiol 2011,49(4),1588-1590","journal-title":"J Clin Microbiol"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1128\/JCM.06860-11","volume":"50","author":"Yuan X.","year":"2012","unstructured":"Yuan X.; Zhang T.; Kawakami K.; Zhu J.; Li H.; Lei J.; Tu S.; Molecular characterization of multidrug- and extensively drug-resistant Mycobacterium tuberculosis strains in Jiangxi, China. J Clin Microbiol 2012,50(7),2404-2413","journal-title":"J Clin Microbiol"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.diagmicrobio.2013.06.031","volume":"77","author":"Du Q.","year":"2013","unstructured":"Du Q.; Dai G.; Long Q.; Yu X.; Dong L.; Huang H.; Xie J.; Mycobacterium tuberculosis rrs A1401G mutation correlates with high-level resistance to kanamycin, amikacin, and capreomycin in clinical isolates from mainland China. Diagn Microbiol Infect Dis 2013,77(2),138-142","journal-title":"Diagn Microbiol Infect Dis"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/1471-2180-14-165","volume":"14","author":"Sowajassatakul A.","year":"2014","unstructured":"Sowajassatakul A.; Prammananan T.; Chaiprasert A.; Phunpruch S.; Molecular characterization of amikacin, kanamycin and capreomycin resistance in M\/XDR-TB strains isolated in Thailand. BMC Microbiol 2014,14(1),165","journal-title":"BMC Microbiol"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jgg.2016.10.002","volume":"44","author":"Islam M.M.","year":"2017","unstructured":"Islam M.M.; Hameed H.M.A.; Mugweru J.; Chhotaray C.; Wang C.; Tan Y.; Liu J.; Li X.; Tan S.; Ojima I.; Yew W.W.; Nuermberger E.; Lamichhane G.; Zhang T.; Drug resistance mechanisms and novel drug targets for tuberculosis therapy. J Genet Genomics 2017,44(1),21-37","journal-title":"J Genet Genomics"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"4590","DOI":"10.1128\/AAC.00753-16","volume":"60","author":"Almeida D.","year":"2016","unstructured":"Almeida D.; Ioerger T.; Tyagi S.; Li S.Y.; Mdluli K.; Andries K.; Grosset J.; Sacchettini J.; Nuermberger E.; Mutations in pepQ confer low-level resistance to bedaquiline and clofazimine in Mycobacterium Tuberculosis. Antimicrob Agents Chemother 2016,60(8),4590-4599","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1248\/bpb.b14-00311","volume":"37","author":"Shimokawa Y.","year":"2014","unstructured":"Shimokawa Y.; Sasahara K.; Yoda N.; Mizuno K.; Umehara K.; Delamanid does not inhibit or induce cytochrome p450 enzymes in vitro. Biol Pharm Bull 2014,37(11),1727-1735","journal-title":"Biol Pharm Bull"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"38434","DOI":"10.1074\/jbc.M112.400994","volume":"287","author":"Grzegorzewicz A.E.","year":"2012","unstructured":"Grzegorzewicz A.E.; Kordul&#xE1;kov&#xE1; J.; Jones V.; Born S.E.M.; Belardinelli J.M.; Vaqui&#xE9; A.; Gundi V.A.K.B.; Madacki J.; Slama N.; Laval F.; Vaubourgeix J.; Crew R.M.; Gicquel B.; Daff&#xE9; M.; Morbidoni H.R.; Brennan P.J.; Qu&#xE9;mard A.; McNeil M.R.; Jackson M.; A common mechanism of inhibition of the Mycobacterium tuberculosis mycolic acid biosynthetic pathway by isoxyl and thiacetazone. J Biol Chem 2012,287(46),38434-38441","journal-title":"J Biol Chem"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1124\/jpet.105.087817","volume":"315","author":"Jia L.","year":"2005","unstructured":"Jia L.; Coward L.; Gorman G.S.; Noker P.E.; Tomaszewski J.E.; Pharmacoproteomic effects of isoniazid, ethambutol and SQ109 on Mycobacterium Tuberculosis H37Rv. J Pharmacol Exp Ther 2005,315,905-911","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=155","first-page":"146","volume":"5","author":"Heath R.J.","year":"2004","unstructured":"Heath R.J.; Rock C.O.; Fatty acid biosynthesis as a target for novel antibacterials. Curr Opin Investig Drugs 2004,5(2),146-153","journal-title":"Curr Opin Investig Drugs"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"391","DOI":"10.7164\/antibiotics.35.391","volume":"35","author":"Oishi H.","year":"1982","unstructured":"Oishi H.; Noto T.; Sasaki H.; Suzuki K.; Hayashi T.; Okazaki H.; Ando K.; Sawada M.; Thiolactomycin, a new antibiotic. I. Taxonomy of the producing organism, fermentation and biological properties. J Antibiot (Tokyo) 1982,35(4),391-395","journal-title":"J Antibiot (Tokyo)"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1054\/tube.2002.0333","volume":"82","author":"Slayden R.A.","year":"2002","unstructured":"Slayden R.A.; Barry C.E.; The role of KasA and KasB in the biosynthesis of meromycolic acids and isoniazid resistance in Mycobacterium tuberculosis. Tuberculosis (Edinb) 2002,82(4-5),149-160","journal-title":"Tuberculosis (Edinb)"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/med.20017","volume":"25","author":"Tripathi R.P.","year":"2005","unstructured":"Tripathi R.P.; Tewari N.; Dwivedi N.; Tiwari V.K.; Fighting tuberculosis: An old disease with new challenges. Med Res Rev 2005,25(1),93-131","journal-title":"Med Res Rev"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2165\/00003495-200161010-00002","volume":"61","author":"Berning S.E.","year":"2001","unstructured":"Berning S.E.; The role of fluoroquinolones in tuberculosis today. Drugs 2001,61(1),9-18","journal-title":"Drugs"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2174\/1389450013348227","volume":"2","author":"Pasqualoto K.F.","year":"2001","unstructured":"Pasqualoto K.F.; Ferreira E.I.; An approach for the rational design of new antituberculosis agents. Curr Drug Targets 2001,2(4),427-437","journal-title":"Curr Drug Targets"},{"key":"ref=161","first-page":"753","volume":"81","author":"Tomioka H.","year":"2006","unstructured":"Tomioka H.; Namba K.; Development of antituberculous drugs: current status and future prospects. Kekkaku 2006,81(12),753-774","journal-title":"Kekkaku"},{"key":"ref=162","first-page":"2492","volume":"50","author":"Daffe M.","year":"2007","unstructured":"Daffe M.; Brennan P.J.; Mcneil M.; C-3 Alkyl\/Arylalkyl-2,3-dideoxy hex-2-enopyranosides as Antitubercular Agents: Synthesis, Biological Evaluation and QSAR Study. J Med Chem 2007,50,2492","journal-title":"J Med Chem"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.tube.2003.08.019","volume":"84","author":"Smith C.V.","year":"2004","unstructured":"Smith C.V.; Sharma V.; Sacchettini J.C.; TB drug discovery: addressing issues of persistence and resistance. Tuberculosis (Edinb) 2004,84(1-2),45-55","journal-title":"Tuberculosis (Edinb)"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S0140-6736(03)14333-4","volume":"362","author":"Frieden T.R.","year":"2003","unstructured":"Frieden T.R.; Sterling T.R.; Munsiff S.S.; Watt C.J.; Dye C.; Tuberculosis. Lancet 2003,362(9387),887-899","journal-title":"Lancet"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1517\/14728222.6.1.21","volume":"6","author":"Khasnobis S.","year":"2002","unstructured":"Khasnobis S.; Escuyer V.E.; Chatterjee D.; Emerging therapeutic targets in tuberculosis: post-genomic era. Expert Opin Ther Targets 2002,6(1),21-40","journal-title":"Expert Opin Ther Targets"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/rr54","volume":"2","author":"Somoskovi A.","year":"2001","unstructured":"Somoskovi A.; Parsons L.M.; Salfinger M.; The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respir Res 2001,2(3),164-168","journal-title":"Respir Res"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/S0966-842X(00)01762-5","volume":"8","author":"Bayles K.W.","year":"2000","unstructured":"Bayles K.W.; The bactericidal action of penicillin: new clues to an unsolved mystery. Trends Microbiol 2000,8(6),274-278","journal-title":"Trends Microbiol"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1126\/science.1119299","volume":"311","author":"Glickman S.W.","year":"2006","unstructured":"Glickman S.W.; Rasiel E.B.; Hamilton C.D.; Kubataev A.; Schulman K.A.; Medicine. A portfolio model of drug development for tuberculosis. Science 2006,311(5765),1246-1247","journal-title":"Science"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0014-827X(02)01229-6","volume":"57","author":"Teodori E.","year":"2002","unstructured":"Teodori E.; Dei S.; Scapecchi S.; Gualtieri F.; The medicinal chemistry of multidrug resistance (MDR) reversing drugs. Farmaco 2002,57(5),385-415","journal-title":"Farmaco"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1164\/ajrccm.163.5.2007122","volume":"163","author":"O\u2019Brien R.J.","year":"2001","unstructured":"O\u2019Brien R.J.; Nunn P.P.; The need for new drugs against tuberculosis. Obstacles, opportunities, and next steps. Am J Respir Crit Care Med 2001,163(5),1055-1058","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1128\/AAC.37.2.183","volume":"37","author":"Ashtekar D.R.","year":"1993","unstructured":"Ashtekar D.R.; Costa-Perira R.; Nagrajan K.; Vishvanathan N.; Bhatt A.D.; Rittel W.; In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1993,37(2),183-186","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1128\/AAC.49.6.2289-2293.2005","volume":"49","author":"Tyagi S.","year":"2005","unstructured":"Tyagi S.; Nuermberger E.; Yoshimatsu T.; Williams K.; Rosenthal I.; Lounis N.; Bishai W.; Grosset J.; Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 2005,49(6),2289-2293","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s10096-004-1109-5","volume":"23","author":"Nuermberger E.","year":"2004","unstructured":"Nuermberger E.; Grosset J.; Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur J Clin Microbiol Infect Dis 2004,23(4),243-255","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1365-2958.2005.04741.x","volume":"57","author":"Tian J.","year":"2005","unstructured":"Tian J.; Bryk R.; Shi S.; Erdjument-Bromage H.; Tempst P.; Nathan C.; Mycobacterium tuberculosis appears to lack &#x3B1;-ketoglutarate dehydrogenase and encodes pyruvate dehydrogenase in widely separated genes. Mol Microbiol 2005,57(3),859-868","journal-title":"Mol Microbiol"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1128\/IAI.74.1.56-63.2006","volume":"74","author":"Shi S.","year":"2006","unstructured":"Shi S.; Ehrt S.; Dihydrolipoamide acyltransferase is critical for Mycobacterium tuberculosis pathogenesis. Infect Immun 2006,74(1),56-63","journal-title":"Infect Immun"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.2174\/0929867054367194","volume":"12","author":"Jain R.","year":"2005","unstructured":"Jain R.; Chen D.; White R.; Patel D.; Yuan Z.; Bacterial Peptide deformylase inhibitors: a new class of antibacterial agents. Curr Med Chem 2005,12(14),1607-1621","journal-title":"Curr Med Chem"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/jac\/dkh054","volume":"53","author":"Cynamon M.H.","year":"2004","unstructured":"Cynamon M.H.; Alvirez-Freites E.; Yeo A.E.; BB-3497, a peptide deformylase inhibitor, is active against Mycobacterium tuberculosis. J Antimicrob Chemother 2004,53(2),403-b-405","journal-title":"J Antimicrob Chemother"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1054\/tuld.1999.0212","volume":"79","author":"Sun Z.","year":"1999","unstructured":"Sun Z.; Zhang Y.; Antituberculosis activity of certain antifungal and antihelmintic drugs. Tuber Lung Dis 1999,79(5),319-320","journal-title":"Tuber Lung Dis"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/00001432-199712000-00007","volume":"10","author":"Groll A.H.","year":"1997","unstructured":"Groll A.H.; Walsh T.J.; Potential new antifungal agents. Curr Opin Infect Dis 1997,10(6),449-458","journal-title":"Curr Opin Infect Dis"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/j.bmcl.2005.02.037","volume":"15","author":"Shindikar A.V.","year":"2005","unstructured":"Shindikar A.V.; Viswanathan C.L.; Novel fluoroquinolones: design, synthesis, and in vivo activity in mice against Mycobacterium tuberculosis H37Rv. Bioorg Med Chem Lett 2005,15(7),1803-1806","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1128\/AAC.00244-06","volume":"50","author":"Petrella S.","year":"2006","unstructured":"Petrella S.; Cambau E.; Chauffour A.; Andries K.; Jarlier V.; Sougakoff W.; Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria. Antimicrob Agents Chemother 2006,50(8),2853-2856","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/S0014-827X(03)00163-0","volume":"58","author":"Dolezal M.","year":"2003","unstructured":"Dolezal M.; Jamp&#xED;lek J.; Osicka Z.; Kune\u0161 J.; Buchta V.; V&#xED;chov&#xE1; P.; Substituted 5-aroylpyrazine-2-carboxylic acid derivatives: synthesis and biological activity. Farmaco 2003,58(11),1105-1111","journal-title":"Farmaco"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/S0960-894X(00)00188-8","volume":"10","author":"Bakkestuen A.K.","year":"2000","unstructured":"Bakkestuen A.K.; Gundersen L.L.; Langli G.; Liu F.; Nols&#xF8;e J.M.J.; 9-Benzylpurines with inhibitory activity against Mycobacterium tuberculosis. Bioorg Med Chem Lett 2000,10(11),1207-1210","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1021\/jm0110284","volume":"45","author":"Gundersen L.L.","year":"2002","unstructured":"Gundersen L.L.; Nissen-Meyer J.; Spilsberg B.; Synthesis and antimycobacterial activity of 6-arylpurines: the requirements for the N-9 substituent in active antimycobacterial purines. J Med Chem 2002,45(6),1383-1386","journal-title":"J Med Chem"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/S0960-894X(01)00266-9","volume":"11","author":"Scozzafava A.","year":"2001","unstructured":"Scozzafava A.; Mastrolorenzo A.; Supuran C.T.; Antimycobacterial activity of 9-sulfonylated\/sulfenylated-6-mercaptopurine derivatives. Bioorg Med Chem Lett 2001,11(13),1675-1678","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"411","DOI":"10.7164\/antibiotics.35.411","volume":"35","author":"Miyakawa S.","year":"1982","unstructured":"Miyakawa S.; Suzuki K.; Noto T.; Harada Y.; Okazaki H.; Thiolactomycin, a new antibiotic. IV. Biological properties and chemotherapeutic activity in mice. J Antibiot (Tokyo) 1982,35(4),411-419","journal-title":"J Antibiot (Tokyo)"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/S0006-291X(83)80050-3","volume":"115","author":"Hayashi T.","year":"1983","unstructured":"Hayashi T.; Yamamoto O.; Sasaki H.; Kawaguchi. A.; Okazaki, H. Hayashi, T.; Yamamoto, O.; Sasaki, H.; Kawaguchi. A.; Okazaki, H. Biochem Biophys Res Commun 1983,115,1108-1113","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0163-7827(01)00012-1","volume":"40","author":"Heath R.J.","year":"2001","unstructured":"Heath R.J.; White S.W.; Rock C.O.; Lipid biosynthesis as a target for antibacterial agents. Prog Lipid Res 2001,40(6),467-497","journal-title":"Prog Lipid Res"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1128\/jb.174.2.508-513.1992","volume":"174","author":"Tsay J.T.","year":"1992","unstructured":"Tsay J.T.; Rock C.O.; Jackowski S.; Overproduction of beta-ketoacyl-acyl carrier protein synthase I imparts thiolactomycin resistance to Escherichia coli K-12. J Bacteriol 1992,174(2),508-513","journal-title":"J Bacteriol"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1099\/00221287-148-10-3101","volume":"148","author":"Douglas J.D.","year":"2002","unstructured":"Douglas J.D.; Senior S.J.; Morehouse C.; Phetsukiri B.; Campbell I.B.; Besra G.S.; Minnikin D.E.; Analogues of thiolactomycin: potential drugs with enhanced anti-mycobacterial activity a aDetails for the preparation of the thiolactomycin analogues shown in Table 1 are available as supplementary data in Microbiology Online ([http:\/\/mic.sgmjournals.org). Microbiology (Reading) 2002,148(10),3101-3109","journal-title":"Microbiology (Reading)"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"12352","DOI":"10.1073\/pnas.95.21.12352","volume":"95","author":"Waller R.F.","year":"1998","unstructured":"Waller R.F.; Keeling P.J.; Donald R.G.K.; Striepen B.; Handman E.; Lang-Unnasch N.; Cowman A.F.; Besra G.S.; Roos D.S.; McFadden G.I.; Nuclear-encoded proteins target to the plastid in Toxoplasma gondii and Plasmodium falciparum. Proc Natl Acad Sci USA 1998,95(21),12352-12357","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1126\/science.288.5463.140","volume":"288","author":"Morita Y.S.","year":"2000","unstructured":"Morita Y.S.; Paul K.S.; Englund P.T.; Specialized fatty acid synthesis in African trypanosomes: myristate for GPI anchors. Science 2000,288(5463),140-143","journal-title":"Science"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1128\/AAC.40.12.2813","volume":"40","author":"Slayden R.A.","year":"1996","unstructured":"Slayden R.A.; Lee R.E.; Armour J.W.; Cooper A.M.; Orme I.M.; Brennan P.J.; Besra G.S.; Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis. Antimicrob Agents Chemother 1996,40(12),2813-2819","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"7425","DOI":"10.1021\/ja00095a063","volume":"116","author":"Johnsson K.","year":"1994","unstructured":"Johnsson K.; Schultz P.G.; Mechanistic studies of the oxidation of isoniazid by the catalase peroxidase from Mycobacterium tuberculosis. J Am Chem Soc 1994,116(16),7425-7426","journal-title":"J Am Chem Soc"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1039\/a605768c","volume":"1","author":"Chambers M.S.","year":"1997","unstructured":"Chambers M.S.; Thomas E.J.; Asymmetric synthesis of 5,5-disubstituted thiotetronic acids using an allyl xanthate to dithiocarbonate rearrangement: total synthesis of (5S)-thiolactomycin with revision of the absolute configuration of the natural. J Chem Soc, Perkin Trans 1 1997,1(4),417-432","journal-title":"J Chem Soc, Perkin Trans 1"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1128\/AAC.44.4.848-852.2000","volume":"44","author":"Kunin C.M.","year":"2000","unstructured":"Kunin C.M.; Ellis W.Y.; Antimicrobial activities of mefloquine and a series of related compounds. Antimicrob Agents Chemother 2000,44(4),848-852","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"4918","DOI":"10.1021\/jm980146x","volume":"41","author":"De D.","year":"1998","unstructured":"De D.; Krogstad F.M.; Byers L.D.; Krogstad D.J.; Structure-activity relationships for antiplasmodial activity among 7-substituted 4-aminoquinolines. J Med Chem 1998,41(25),4918-4926","journal-title":"J Med Chem"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1128\/AAC.48.7.2415-2423.2004","volume":"48","author":"Li X.Z.","year":"2004","unstructured":"Li X.Z.; Zhang L.; Nikaido H.; Efflux pump-mediated intrinsic drug resistance in Mycobacterium smegmatis. Antimicrob Agents Chemother 2004,48(7),2415-2423","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/S0223-5234(99)00124-5","volume":"34","author":"Cocco M.T.","year":"1999","unstructured":"Cocco M.T.; Congiu C.; Onnis V.; Pusceddu M.C.; Schivo M.L.; De Logu A.; Synthesis and antimycobacterial activity of some isonicotinoylhydrazones. Eur J Med Chem 1999,34(12),1071-1076","journal-title":"Eur J Med Chem"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"5419","DOI":"10.1016\/j.bmcl.2007.07.027","volume":"17","author":"Kamal A.","year":"2007","unstructured":"Kamal A.; Kaleem Ahmed S.; Srinivasa Reddy K.; Khan M.N.A.; Shetty R.V.C.R.N.C.; Siddhardha B.; Murthy U.S.N.; Khan I.A.; Kumar M.; Sharma S.; Ram A.B.; Anti-tubercular agents. Part IV: Synthesis and antimycobacterial evaluation of nitroheterocyclic-based 1,2,4-benzothiadiazines. Bioorg Med Chem Lett 2007,17(19),5419-5422","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1128\/AAC.42.11.3035","volume":"42","author":"Deidda D.","year":"1998","unstructured":"Deidda D.; Lampis G.; Fioravanti R.; Biava M.; Porretta G.C.; Zanetti S.; Pompei R.; Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic Mycobacterium tuberculosis strains. Antimicrob Agents Chemother 1998,42(11),3035-3037","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1021\/jm049952w","volume":"48","author":"Jaso A.","year":"2005","unstructured":"Jaso A.; Zarranz B.; Aldana I.; Monge A.; Synthesis of new quinoxaline-2-carboxylate 1,4-dioxide derivatives as anti-Mycobacterium tuberculosis agents. J Med Chem 2005,48(6),2019-2025","journal-title":"J Med Chem"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1021\/jm000149l","volume":"43","author":"Jones P.B.","year":"2000","unstructured":"Jones P.B.; Parrish N.M.; Houston T.A.; Stapon A.; Bansal N.P.; Dick J.D.; Townsend C.A.; A new class of antituberculosis agents. J Med Chem 2000,43(17),3304-3314","journal-title":"J Med Chem"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nrmicro840","volume":"2","author":"Koul A.","year":"2004","unstructured":"Koul A.; Herget T.; Klebl B.; Ullrich A.; Interplay between mycobacteria and host signalling pathways. Nat Rev Microbiol 2004,2(3),189-202","journal-title":"Nat Rev Microbiol"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"12151","DOI":"10.1073\/pnas.0702842104","volume":"104","author":"Scherr N.","year":"2007","unstructured":"Scherr N.; Honnappa S.; Kunz G.; Mueller P.; Jayachandran R.; Winkler F.; Pieters J.; Steinmetz M.O.; Structural basis for the specific inhibition of protein kinase G, a virulence factor of Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2007,104(29),12151-12156","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"9613","DOI":"10.1021\/ja0727520","volume":"129","author":"Soellner M.B.","year":"2007","unstructured":"Soellner M.B.; Rawls K.A.; Grundner C.; Alber T.; Ellman J.A.; Fragment-based substrate activity screening method for the identification of potent inhibitors of the Mycobacterium tuberculosis phosphatase PtpB. J Am Chem Soc 2007,129(31),9613-9615","journal-title":"J Am Chem Soc"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2174\/0929867043455765","volume":"11","author":"Stephenson K.","year":"2004","unstructured":"Stephenson K.; Hoch J.A.; Developing inhibitors to selectively target two-component and phosphorelay signal transduction systems of pathogenic microorganisms. Curr Med Chem 2004,11(6),765-773","journal-title":"Curr Med Chem"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"38900","DOI":"10.1074\/jbc.M006633200","volume":"275","author":"Stephenson K.","year":"2000","unstructured":"Stephenson K.; Yamaguchi Y.; Hoch J.A.; The mechanism of action of inhibitors of bacterial two-component signal transduction systems. J Biol Chem 2000,275(49),38900-38904","journal-title":"J Biol Chem"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.farmac.2005.02.002","volume":"60","author":"Matyk J.","year":"2005","unstructured":"Matyk J.; Waisser K.; Dra&#x17E;kov&#xE1; K.; Kune\u0161 J.; Klime\u0161ov&#xE1; V.; Pal&#xE1;t K.; Kaustov&#xE1; J.; Heterocyclic isosters of antimycobacterial salicylanilides. Farmaco 2005,60(5),399-408","journal-title":"Farmaco"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/ardp.200600093","volume":"339","author":"Waisser K.","year":"2006","unstructured":"Waisser K.; Matyk J.; Divi\u0161ov&#xE1; H.; Hus&#xE1;kov&#xE1; P.; Kune\u0161 J.; Klime\u0161ov&#xE1; V.; Kaustov&#xE1; J.; M&#xF6;llmann U.; Dahse H.M.; Miko M.; The oriented development of antituberculotics: salicylanilides. Arch Pharm (Weinheim) 2006,339(11),616-620","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/S0966-842X(00)01734-0","volume":"8","author":"Av-Gay Y.","year":"2000","unstructured":"Av-Gay Y.; Everett M.; The eukaryotic-like Ser\/Thr protein kinases of Mycobacterium tuberculosis. Trends Microbiol 2000,8(5),238-244","journal-title":"Trends Microbiol"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1126\/science.1099384","volume":"304","author":"Walburger A.","year":"2004","unstructured":"Walburger A.; Koul A.; Ferrari G.; Nguyen L.; Prescianotto-Baschong C.; Huygen K.; Klebl B.; Thompson C.; Bacher G.; Pieters J.; Protein kinase G from pathogenic mycobacteria promotes survival within macrophages. Science 2004,304(5678),1800-1804","journal-title":"Science"},{"key":"ref=213","author":"Koul A.","year":"2004","unstructured":"Koul A.; Klebl B.; Mueller G.; Missio A.; Schwab W.; Hafenbradl D.; Neumann L.; Sommer M.N.; Mueller S.; Hoppe E.; Freisleben A.; Backes A.; Hartung C.; Felber B.; Zech B.; Engkvist O.; Keri G.; Oerfi L.; Banhegyi P.; Greff Z.; Preparation of hetero-bicyclic fused thieno-pyran compounds as antibacterial, antiviral, antitumor, and pharmaceutically active agents. 2004"},{"key":"ref=214","author":"Pato J.","year":"2004","unstructured":"Pato J.; Keri G.; Orfi L.; Waczek F.; Horvath Z.; Banhegyi P.; Szabadkai I.; Marosfalvi J.; Hegymegi-Barakonyi B.; Szekelyhidi Zs.; Greff Z.; Choidas A.; Bacher G.; Missio A.; Koul A.; Inhibitors of mycobacterial serine\/threonine protein kinases for the treatment of mycobacterial infections. 2004"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ijantimicag.2004.11.003","volume":"25","author":"Zanetti S.","year":"2005","unstructured":"Zanetti S.; Sechi L.A.; Molicotti P.; Cannas S.; Carta A.; Bua A.; Deriu A.; Paglietti G.; In vitro activity of new quinoxalin 1,4-dioxide derivatives against strains of Mycobacterium tuberculosis and other mycobacteria. Int J Antimicrob Agents 2005,25(2),179-181","journal-title":"Int J Antimicrob Agents"},{"key":"ref=216","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/(SICI)1098-1128(199811)18:6<363:AID-MED1>3.0.CO;2-I","volume":"18","author":"Mitscher L.A.","year":"1998","unstructured":"Mitscher L.A.; Baker W.; Tuberculosis: A search for novel therapy starting with natural products. Med Res Rev 1998,18(6),363-374","journal-title":"Med Res Rev"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1378\/chest.124.4.1482","volume":"124","author":"Field S.K.","year":"2003","unstructured":"Field S.K.; Cowie R.L.; Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. Chest 2003,124(4),1482-1486","journal-title":"Chest"},{"key":"ref=218","author":"Ramneatu O.M.","year":"2000","unstructured":"Ramneatu O.M.; Lowary T.L.; Poster CARB-52 presented at the 220th National Meeting of the American Chemical Society, Washington D.C.; USA, 20-24 August, Derwent World Drug Alert abstract WD-2000-011652.2000"},{"key":"ref=219","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/S0149-2918(00)80053-3","volume":"22","author":"Bertino J.","year":"2000","unstructured":"Bertino J.; Fish D.; The safety profile of the fluoroquinolones. Clin Ther 2000,22(7),798-817","journal-title":"Clin Ther"},{"key":"ref=220","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1128\/AAC.43.5.1189","volume":"43","author":"Cynamon M.H.","year":"1999","unstructured":"Cynamon M.H.; Klemens S.P.; Sharpe C.A.; Chase S.; Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 1999,43(5),1189-1191","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=221","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1021\/jm9509556","volume":"39","author":"Brickner S.J.","year":"1996","unstructured":"Brickner S.J.; Hutchinson D.K.; Barbachyn M.R.; Manninen P.R.; Ulanowicz D.A.; Garmon S.A.; Grega K.C.; Hendges S.K.; Toops D.S.; Ford C.W.; Zurenko G.E.; Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. J Med Chem 1996,39(3),673-679","journal-title":"J Med Chem"},{"key":"ref=222","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1128\/AAC.32.8.1218","volume":"32","author":"Eustice D.C.","year":"1988","unstructured":"Eustice D.C.; Feldman P.A.; Zajac I.; Slee A.M.; Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis. Antimicrob Agents Chemother 1988,32(8),1218-1222","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=223","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2165\/00003495-200059010-00002","volume":"59","author":"Diekema D.J.","year":"2000","unstructured":"Diekema D.J.; Jones R.N.; Oxazolidinones. Drugs 2000,59(1),7-16","journal-title":"Drugs"},{"key":"ref=224","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S0924-8579(00)00290-9","volume":"16","author":"Corti G.","year":"2000","unstructured":"Corti G.; Cinelli R.; Paradisi F.; Clinical and microbiologic efficacy and safety profile of linezolid, a new oxazolidinone antibiotic. Int J Antimicrob Agents 2000,16(4),527-530","journal-title":"Int J Antimicrob Agents"},{"key":"ref=225","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1128\/AAC.40.4.839","volume":"40","author":"Zurenko G.E.","year":"1996","unstructured":"Zurenko G.E.; Yagi B.H.; Schaadt R.D.; Allison J.W.; Kilburn J.O.; Glickman S.E.; Hutchinson D.K.; Barbachyn M.R.; Brickner S.J.; In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996,40(4),839-845","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=226","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1016\/S0960-894X(98)00628-3","volume":"8","author":"Spino C.","year":"1998","unstructured":"Spino C.; Dodier M.; Sotheeswaran S.; Anti-HIV coumarins from calophyllum seed oil. Bioorg Med Chem Lett 1998,8(24),3475-3478","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=227","first-page":"1083","volume":"151","author":"Jagannath C.","year":"1995","unstructured":"Jagannath C.; Reddy M.V.; Kailasam S.; O\u2019Sullivan J.F.; Gangadharam P.R.; Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis. In vitro, intracellular, and in vivo studies. Am J Respir Crit Care Med 1995,151(4),1083-1086","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=228","doi-asserted-by":"crossref","first-page":"802","DOI":"10.22270\/jddt.v9i3-s.2777","volume":"9","author":"Saxena N.","year":"2019","unstructured":"Saxena N.; Srivastava N.; Shukla P.; Tripathi G.K.; The drug discovery development for treatment of tuberculosis. J Drug Deliv Ther 2019,9(3-s),802-819","journal-title":"J Drug Deliv Ther"},{"key":"ref=229","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0968-0896(00)00061-4","volume":"8","author":"Ragno R.","year":"2000","unstructured":"Ragno R.; Marshall G.R.; Di Santo R.; Costi R.; Massa S.; Rompei R.; Artico M.; Antimycobacterial pyrroles: synthesis, anti- Mycobacterium tuberculosis activity and QSAR studies. Bioorg Med Chem 2000,8(6),1423-1432","journal-title":"Bioorg Med Chem"},{"key":"ref=230","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1128\/AAC.48.12.4550-4555.2004","volume":"48","author":"Nikonenko B.V.","year":"2004","unstructured":"Nikonenko B.V.; Samala R.; Einck L.; Nacy C.A.; Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2004,48(12),4550-4555","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=231","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1128\/AAC.40.12.2809","volume":"40","author":"Kelly B.P.","year":"1996","unstructured":"Kelly B.P.; Furney S.K.; Jessen M.T.; Orme I.M.; Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996,40(12),2809-2812","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=232","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1111\/j.1365-2958.2004.04346.x","volume":"54","author":"Schl&#xFC;nzen F.","year":"2004","unstructured":"Schl&#xFC;nzen F.; Pyetan E.; Fucini P.; Yonath A.; Harms J.M.; Inhibition of peptide bond formation by pleuromutilins: the structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin. Mol Microbiol 2004,54(5),1287-1294","journal-title":"Mol Microbiol"},{"key":"ref=233","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1128\/AAC.00131-06","volume":"50","author":"Long K.S.","year":"2006","unstructured":"Long K.S.; Poehlsgaard J.; Kehrenberg C.; Schwarz S.; Vester B.; The Cfr rRNA methyltransferase confers resistance to Phenicols, Lincosamides, Oxazolidinones, Pleuromutilins, and Streptogramin A antibiotics. Antimicrob Agents Chemother 2006,50(7),2500-2505","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=234","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1093\/jac\/dkh408","volume":"54","author":"Parrish N.M.","year":"2004","unstructured":"Parrish N.M.; Ko C.G.; Hughes M.A.; Townsend C.A.; Dick J.D.; Effect ofn-octanesulphonylacetamide (OSA) on ATP and protein expression in Mycobacterium bovis BCG. J Antimicrob Chemother 2004,54(4),722-729","journal-title":"J Antimicrob Chemother"},{"key":"ref=235","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1093\/jac\/dki319","volume":"56","author":"Protopopova M.","year":"2005","unstructured":"Protopopova M.; Hanrahan C.; Nikonenko B.; Samala R.; Chen P.; Gearhart J.; Einck L.; Nacy C.A.; Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother 2005,56(5),968-974","journal-title":"J Antimicrob Chemother"},{"key":"ref=236","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1093\/jac\/46.6.917","volume":"46","author":"Murugasu-Oei B.","year":"2000","unstructured":"Murugasu-Oei B.; Dick T.; Bactericidal activity of nitrofurans against growing and dormant Mycobacterium bovis BCG. J Antimicrob Chemother 2000,46(6),917-919","journal-title":"J Antimicrob Chemother"},{"key":"ref=237","doi-asserted-by":"publisher","first-page":"5276","DOI":"10.1021\/jm049972y","volume":"47","author":"Tangallapally R.P.","year":"2004","unstructured":"Tangallapally R.P.; Yendapally R.; Lee R.E.; Hevener K.; Jones V.C.; Lenaerts A.J.M.; McNeil M.R.; Wang Y.; Franzblau S.; Lee R.E.; Synthesis and evaluation of nitrofuranylamides as novel antituberculosis agents. J Med Chem 2004,47(21),5276-5283","journal-title":"J Med Chem"},{"key":"ref=238","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1093\/femsre\/fuz016","volume":"43","author":"Maitra A.","year":"2019","unstructured":"Maitra A.; Munshi T.; Healy J.; Martin L.T.; Vollmer W.; Keep N.H.; Bhakta S.; Bhakta S.; Cell wall peptidoglycan in Mycobacterium tuberculosis: An Achilles\u2019 heel for the TB-causing pathogen. FEMS Microbiol Rev 2019,43(5),548-575","journal-title":"FEMS Microbiol Rev"},{"key":"ref=239","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1128\/MMBR.00028-07","volume":"72","author":"Hett E.C.","year":"2008","unstructured":"Hett E.C.; Rubin E.J.; Bacterial growth and cell division: a mycobacterial perspective. Microbiol Mol Biol Rev 2008,72(1),126-156","journal-title":"Microbiol Mol Biol Rev"},{"key":"ref=240","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1128\/AAC.04222-14","volume":"59","author":"Danilchanka O.","year":"2015","unstructured":"Danilchanka O.; Pires D.; Anes E.; Niederweis M.; The Mycobacterium tuberculosis outer membrane channel protein CpnT confers susceptibility to toxic molecules. Antimicrob Agents Chemother 2015,59(4),2328-2336","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=241","doi-asserted-by":"publisher","first-page":"12807","DOI":"10.1038\/s41598-017-12718-4","volume":"7","author":"Chiaradia L.","year":"2017","unstructured":"Chiaradia L.; Lefebvre C.; Parra J.; Marcoux J.; Burlet-Schiltz O.; Etienne G.; Tropis M.; Daff&#xE9; M.; Dissecting the mycobacterial cell envelope and defining the composition of the native mycomembrane. Sci Rep 2017,7(1),12807","journal-title":"Sci Rep"},{"key":"ref=242","doi-asserted-by":"publisher","first-page":"4376","DOI":"10.1073\/pnas.0711159105","volume":"105","author":"Pandey A.K.","year":"2008","unstructured":"Pandey A.K.; Sassetti C.M.; Mycobacterial persistence requires the utilization of host cholesterol. Proc Natl Acad Sci USA 2008,105(11),4376-4380","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=243","doi-asserted-by":"publisher","first-page":"e112426","DOI":"10.1371\/journal.pone.0112426","volume":"9","author":"Raffetseder J.","year":"2014","unstructured":"Raffetseder J.; Pienaar E.; Blomgran R.; Eklund D.; Patcha Brodin V.; Andersson H.; Welin A.; Lerm M.; Replication rates of Mycobacterium tuberculosis in human macrophages do not correlate with mycobacterial antibiotic susceptibility. PLoS One 2014,9(11),e112426","journal-title":"PLoS One"},{"key":"ref=244","doi-asserted-by":"crossref","first-page":"258","DOI":"10.22159\/ajpcr.2016.v9s3.14913","volume":"9","author":"Goswam A.","year":"2016","unstructured":"Goswam A.; Chakraborty U.; Bhattacharya B.; Pal N.K.; Association of generation time with anti-tubercular drug(s) resistance pattern of Mycobacterium Tuberculosis isolates among treatment failure pulmonary tuberculosis patients. Asian J Pharm Clin Res 2016,9(1),258-261","journal-title":"Asian J Pharm Clin Res"},{"key":"ref=245","doi-asserted-by":"publisher","first-page":"e1001065","DOI":"10.1371\/journal.pbio.1001065","volume":"9","author":"Baek S.H.","year":"2011","unstructured":"Baek S.H.; Li A.H.; Sassetti C.M.; Metabolic regulation of mycobacterial growth and antibiotic sensitivity. PLoS Biol 2011,9(5),e1001065","journal-title":"PLoS Biol"},{"key":"ref=246","doi-asserted-by":"publisher","first-page":"5017","DOI":"10.1128\/JB.186.15.5017-5030.2004","volume":"186","author":"Daniel J.","year":"2004","unstructured":"Daniel J.; Deb C.; Dubey V.S.; Sirakova T.D.; Abomoelak B.; Morbidoni H.R.; Kolattukudy P.E.; Induction of a novel class of diacylglycerol acyltransferases and triacylglycerol accumulation in Mycobacterium tuberculosis as it goes into a dormancy-like state in culture. J Bacteriol 2004,186(15),5017-5030","journal-title":"J Bacteriol"},{"key":"ref=247","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.1038\/s41598-018-22343-4","volume":"8","author":"Baker J.J.","year":"2018","unstructured":"Baker J.J.; Abramovitch R.B.; Genetic and metabolic regulation of Mycobacterium tuberculosis acid growth arrest. Sci Rep 2018,8(1),4168","journal-title":"Sci Rep"},{"key":"ref=248","doi-asserted-by":"publisher","first-page":"a021121","DOI":"10.1101\/cshperspect.a021121","volume":"5","author":"Warner D.F.","year":"2015","unstructured":"Warner D.F.; Mycobacterium tuberculosis Metabolism. Cold Spring Harb Perspect Med 2015,5(4),a021121","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=249","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s00204-016-1727-6","volume":"90","author":"Nguyen L.","year":"2016","unstructured":"Nguyen L.; Antibiotic resistance mechanisms in M. tuberculosis: an update. Arch Toxicol 2016,90(7),1585-1604","journal-title":"Arch Toxicol"},{"key":"ref=250","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1074\/jbc.273.1.645","volume":"273","author":"Knutson K.L.","year":"1998","unstructured":"Knutson K.L.; Hmama Z.; Herrera-Velit P.; Rochford R.; Reiner N.E.; Lipoarabinomannan of Mycobacterium tuberculosis promotes protein tyrosine dephosphorylation and inhibition of mitogen-activated protein kinase in human mononuclear phagocytes. Role of the Src homology 2 containing tyrosine phosphatase 1. J Biol Chem 1998,273(1),645-652","journal-title":"J Biol Chem"},{"key":"ref=251","doi-asserted-by":"publisher","first-page":"378","DOI":"10.34297\/AJBSR.2020.07.001181","volume":"7","author":"Abraham A.O.","year":"2020","unstructured":"Abraham A.O.; Nasiru A.U.; Abdulazeez A.K.; Seun O.O.; Ogonna D.W.; Mechanism of drug resistance in Mycobacterium Tuberculosis. American Journal of Biomedical Science and Research 2020,7(5),378-383","journal-title":"American Journal of Biomedical Science and Research"},{"key":"ref=252","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/0923-2508(93)90023-U","volume":"144","author":"Kochi A.","year":"1993","unstructured":"Kochi A.; Vareldzis B.; Styblo K.; Multidrug-resistant tuberculosis and its control. Res Microbiol 1993,144(2),104-110","journal-title":"Res Microbiol"},{"key":"ref=253","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/S0140-6736(87)91127-5","volume":"330","author":"Strang J.I.G.","year":"1987","unstructured":"Strang J.I.G.; Gibson D.G.; Nunn A.J.; Kakaza H.H.S.; Girling D.J.; Fox W.; Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei. Lancet 1987,330(8573),1418-1422","journal-title":"Lancet"},{"key":"ref=254","first-page":"174","volume":"4","author":"Damtie D.","year":"2014","unstructured":"Damtie D.; Woldeyohannes D.; Mathewos B.; Review on Molecular mechanism of first line antibiotic resistance in Mycobacterium Tuberculosis. Mycobact Dis 2014,4(6),174","journal-title":"Mycobact Dis"},{"key":"ref=255","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1128\/AAC.01541-12","volume":"57","author":"de Vos M.","year":"2013","unstructured":"de Vos M.; M&#xFC;ller B.; Borrell S.; Black P.A.; van Helden P.D.; Warren R.M.; Gagneux S.; Victor T.C.; Putative compensatory mutations in the rpoC gene of rifampin-resistant Mycobacterium tuberculosis are associated with ongoing transmission. Antimicrob Agents Chemother 2013,57(2),827-832","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=256","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1128\/AAC.44.4.1075-1077.2000","volume":"44","author":"Heep M.","year":"2000","unstructured":"Heep M.; Rieger U.; Beck D.; Lehn N.; Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000,44(4),1075-1077","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=257","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/0140-6736(93)90417-F","volume":"341","author":"Telenti A.","year":"1993","unstructured":"Telenti A.; Imboden P.; Marchesi F.; Matter L.; Schopfer K.; Bodmer T.; Lowrie D.; Colston M.J.; Cole S.; Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993,341(8846),647-651","journal-title":"Lancet"},{"key":"ref=258","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1128\/jcm.32.4.1095-1098.1994","volume":"32","author":"Kapur V.","year":"1994","unstructured":"Kapur V.; Li L.L.; Iordanescu S.; Hamrick M.R.; Wanger A.; Kreiswirth B.N.; Musser J.M.; Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase beta subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas. J Clin Microbiol 1994,32(4),1095-1098","journal-title":"J Clin Microbiol"},{"key":"ref=259","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/jac\/42.5.621","volume":"42","author":"Yang B.","year":"1998","unstructured":"Yang B.; Koga H.; Ohno H.; Ogawa K.; Fukuda M.; Hirakata Y.; Maesaki S.; Tomono K.; Tashiro T.; Kohno S.; Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J Antimicrob Chemother 1998,42(5),621-628","journal-title":"J Antimicrob Chemother"},{"key":"ref=260","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/j.1469-0691.2004.00917.x","volume":"10","author":"Cavusoglu C.","year":"2004","unstructured":"Cavusoglu C.; Karaca-Derici Y.; Bilgic A.; In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Clin Microbiol Infect 2004,10(7),662-665","journal-title":"Clin Microbiol Infect"},{"key":"ref=261","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1164\/ajrccm.164.1.2101133","volume":"164","author":"Burman W.J.","year":"2001","unstructured":"Burman W.J.; Jones B.; Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. Am J Respir Crit Care Med 2001,164(1),7-12","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=262","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1074\/jbc.272.5.2834","volume":"272","author":"Johnsson K.","year":"1997","unstructured":"Johnsson K.; Froland W.A.; Schultz P.G.; Overexpression, purification, and characterization of the catalase-peroxidase KatG from Mycobacterium tuberculosis. J Biol Chem 1997,272(5),2834-2840","journal-title":"J Biol Chem"},{"key":"ref=263","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.5588\/ijtld.15.0864","volume":"20","author":"Bollela V.R.","year":"2016","unstructured":"Bollela V.R.; Namburete E.I.; Feliciano C.S.; Macheque D.; Harrison L.H.; Caminero J.A.; Detection of kat G and inh A mutations to guide isoniazid and ethionamide use for drug-resistant tuberculosis. Int J Tuberc Lung Dis 2016,20(8),1099-1104","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref=264","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1038\/s41598-018-21378-x","volume":"8","author":"Lempens P.","year":"2018","unstructured":"Lempens P.; Meehan C.J.; Vandelannoote K.; Fissette K.; de Rijk P.; Van Deun A.; Rigouts L.; de Jong B.C.; Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations. Sci Rep 2018,8(1),3246","journal-title":"Sci Rep"},{"key":"ref=265","doi-asserted-by":"publisher","first-page":"e00974","DOI":"10.1128\/AAC.00974-18","volume":"62","author":"Kandler J.L.","year":"2018","unstructured":"Kandler J.L.; Mercante A.D.; Dalton T.L.; Ezewudo M.N.; Cowan L.S.; Burns S.P.; Metchock B.; Cegielski P.; Posey J.E.; Validation of novel Mycobacterium tuberculosis isoniazid resistance mutations not detectable by common molecular tests. Antimicrob Agents Chemother 2018,62(10),e00974-e18","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=266","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1128\/AAC.00112-06","volume":"50","author":"Hazb&#xF3;n M.H.","year":"2006","unstructured":"Hazb&#xF3;n M.H.; Brimacombe M.; Bobadilla del Valle M.; Cavatore M.; Guerrero M.I.; Varma-Basil M.; Billman-Jacobe H.; Lavender C.; Fyfe J.; Garc&#xED;a-Garc&#xED;a L.; Le&#xF3;n C.I.; Bose M.; Chaves F.; Murray M.; Eisenach K.D.; Sifuentes-Osornio J.; Cave M.D.; Ponce de Le&#xF3;n A.; Alland D.; Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2006,50(8),2640-2649","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=267","doi-asserted-by":"publisher","first-page":"1701752","DOI":"10.1183\/13993003.01752-2017","volume":"50","author":"Chesov D.","year":"2017","unstructured":"Chesov D.; Ciobanu N.; Lange C.; Sch&#xF6;n T.; Heyckendorf J.; Crudu V.; Lack of evidence of isoniazid efficacy for the treatment of MDR\/XDR-TB in the presence of the katG 315T mutation. Eur Respir J 2017,50(4),1701752","journal-title":"Eur Respir J"},{"key":"ref=268","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1128\/AAC.49.6.2218-2225.2005","volume":"49","author":"Parsons L.M.","year":"2005","unstructured":"Parsons L.M.; Salfinger M.; Clobridge A.; Dormandy J.; Mirabello L.; Polletta V.L.; Sanic A.; Sinyavskiy O.; Larsen S.C.; Driscoll J.; Zickas G.; Taber H.W.; Phenotypic and molecular characterization of Mycobacterium tuberculosis isolates resistant to both isoniazid and ethambutol. Antimicrob Agents Chemother 2005,49(6),2218-2225","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=269","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/mmi.12476","volume":"91","author":"Ando H.","year":"2014","unstructured":"Ando H.; Miyoshi-Akiyama T.; Watanabe S.; Kirikae T.; A silent mutation in mabA confers isoniazid resistance on Mycobacterium tuberculosis. Mol Microbiol 2014,91(3),538-547","journal-title":"Mol Microbiol"},{"key":"ref=270","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/S0140-6736(83)90943-1","volume":"322","author":"P&#xF6;so H.","year":"1983","unstructured":"P&#xF6;so H.; Paulin L.; Brander E.; Specific inhibition of spermidine synthase from mycobacteria by ethambutol. Lancet 1983,322(8364),1418","journal-title":"Lancet"},{"key":"ref=271","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1128\/AAC.49.9.3794-3802.2005","volume":"49","author":"Hazb&#xF3;n M.H.","year":"2005","unstructured":"Hazb&#xF3;n M.H.; Bobadilla del Valle M.; Guerrero M.I.; Varma-Basil M.; Filliol I.; Cavatore M.; Colangeli R.; Safi H.; Billman-Jacobe H.; Lavender C.; Fyfe J.; Garc&#xED;a-Garc&#xED;a L.; Davidow A.; Brimacombe M.; Le&#xF3;n C.I.; Porras T.; Bose M.; Chaves F.; Eisenach K.D.; Sifuentes-Osornio J.; Ponce de Le&#xF3;n A.; Cave M.D.; Alland D.; Role of embB codon 306 mutations in Mycobacterium tuberculosis revisited: a novel association with broad drug resistance and IS6110 clustering rather than ethambutol resistance. Antimicrob Agents Chemother 2005,49(9),3794-3802","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=272","first-page":"1577","volume":"62","author":"Gale E.F.","year":"1981","unstructured":"Gale E.F.; Cundliffe E.; Reynolds P.E.; Richmond M.H.; Waring M.J.; The molecular basis of antibiotic action. The Mol Basis Antibiot. Act 1981,62(9),1577-1578","journal-title":"Act"},{"key":"ref=273","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1093\/jac\/dkq120","volume":"65","author":"Plinke C.","year":"2010","unstructured":"Plinke C.; Cox H.S.; Zarkua N.; Karimovich H.A.; Braker K.; Diel R.; R&#xFC;sch-Gerdes S.; Feuerriegel S.; Niemann S.; embCAB sequence variation among ethambutol-resistant Mycobacterium tuberculosis isolates without embB306 mutation. J Antimicrob Chemother 2010,65(7),1359-1367","journal-title":"J Antimicrob Chemother"},{"key":"ref=274","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.tube.2006.05.004","volume":"87","author":"Ahmad S.","year":"2007","unstructured":"Ahmad S.; Jaber A.A.; Mokaddas E.; Frequency of embB codon 306 mutations in ethambutol-susceptible and -resistant clinical Mycobacterium tuberculosis isolates in Kuwait. Tuberculosis (Edinb) 2007,87(2),123-129","journal-title":"Tuberculosis (Edinb)"},{"key":"ref=275","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1089\/mdr.2017.0294","volume":"24","author":"Al-Mutairi N.M.","year":"2018","unstructured":"Al-Mutairi N.M.; Ahmad S.; Mokaddas E.; Molecular screening versus phenotypic susceptibility testing of multidrug-resistant Mycobacterium tuberculosis isolates for streptomycin and ethambutol. Microb Drug Resist 2018,24(7),923-931","journal-title":"Microb Drug Resist"},{"key":"ref=276","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.tube.2018.11.006","volume":"114","author":"Tulyaprawat O.","year":"2019","unstructured":"Tulyaprawat O.; Chaiprasert A.; Chongtrakool P.; Suwannakarn K.; Ngamskulrungroj P.; Association of ubiA mutations and high-level of ethambutol resistance among Mycobacterium tuberculosis Thai clinical isolates. Tuberculosis (Edinb) 2019,114,42-46","journal-title":"Tuberculosis (Edinb)"},{"key":"ref=277","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12879-019-3764-2","volume":"19","year":"2019","unstructured":"khan, M.T.; Malik, S.I.; Ali, S.; Masood, N.; Nadeem, T.; Khan, A.S.; Afzal, M.T. Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan. BMC Infect Dis 2019,19(1),116","journal-title":"BMC Infect Dis"},{"key":"ref=278","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.advms.2015.09.007","volume":"61","author":"Njire M.","year":"2016","unstructured":"Njire M.; Tan Y.; Mugweru J.; Wang C.; Guo J.; Yew W.; Tan S.; Zhang T.; Pyrazinamide resistance in Mycobacterium tuberculosis: Review and update. Adv Med Sci 2016,61(1),63-71","journal-title":"Adv Med Sci"},{"key":"ref=279","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/emi.2017.73","volume":"6","author":"Huy N.Q.","year":"2017","unstructured":"Huy N.Q.; Lucie C.; Hoa T.T.T.; Hung N.V.; Lan N.T.N.; Son N.T.; Nhung N.V.; Anh D.D.; Anne-Laure B.; Van Anh N.T.; Molecular analysis of pyrazinamide resistance in Mycobacterium tuberculosis in Vietnam highlights the high rate of pyrazinamide resistance-associated mutations in clinical isolates. Emerg Microbes Infect 2017,6(1),1-7","journal-title":"Emerg Microbes Infect"},{"key":"ref=280","first-page":"918","volume":"38","author":"Zhang Y.J.","year":"2016","unstructured":"Zhang Y.J.; Li X.J.; Mi K.X.; Mechanisms of fluoroquinolone resistance in Mycobacterium tuberculosis. Yi Chuan 2016,38(10),918-927","journal-title":"Yi Chuan"},{"key":"ref=281","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/bmj.2.4588.1009","volume":"2","author":"Crofton J.","year":"1948","unstructured":"Crofton J.; Mitchison D.A.; Streptomycin resistance in pulmonary tuberculosis. BMJ 1948,2(4588),1009-1015","journal-title":"BMJ"},{"key":"ref=282","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/327389a0","volume":"327","author":"Moazed D.","year":"1987","unstructured":"Moazed D.; Noller H.F.; Interaction of antibiotics with functional sites in 16S ribosomal RNA. Nature 1987,327(6121),389-394","journal-title":"Nature"},{"key":"ref=283","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1128\/AAC.46.2.267-274.2002","volume":"46","author":"Gillespie S.H.","year":"2002","unstructured":"Gillespie S.H.; Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob Agents Chemother 2002,46(2),267-274","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=284","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/j.1365-2958.2006.05585.x","volume":"63","author":"Okamoto S.","year":"2007","unstructured":"Okamoto S.; Tamaru A.; Nakajima C.; Nishimura K.; Tanaka Y.; Tokuyama S.; Suzuki Y.; Ochi K.; Loss of a conserved 7\u2010methylguanosine modification in 16S rRNA confers low\u2010level streptomycin resistance in bacteria. Mol Microbiol 2007,63(4),1096-1106","journal-title":"Mol Microbiol"},{"key":"ref=285","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1128\/AAC.01570-07","volume":"52","author":"Spies F.S.","year":"2008","unstructured":"Spies F.S.; Almeida da Silva P.E.; Ribeiro M.O.; Rossetti M.L.; Zaha A.; Identification of mutations related to streptomycin resistance in clinical isolates of Mycobacterium tuberculosis and possible involvement of efflux mechanism. Antimicrob Agents Chemother 2008,52(8),2947-2949","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=286","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1365-2958.2004.04120.x","volume":"53","author":"Rengarajan J.","year":"2004","unstructured":"Rengarajan J.; Sassetti C.M.; Naroditskaya V.; Sloutsky A.; Bloom B.R.; Rubin E.J.; The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria. Mol Microbiol 2004,53(1),275-282","journal-title":"Mol Microbiol"},{"key":"ref=287","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1128\/AAC.01775-13","volume":"58","author":"Zhao F.","year":"2014","unstructured":"Zhao F.; Wang X.D.; Erber L.N.; Luo M.; Guo A.; Yang S.; Gu J.; Turman B.J.; Gao Y.; Li D.; Cui Z.; Zhang Z.; Bi L.; Baughn A.D.; Zhang X.E.; Deng J.Y.; Binding pocket alterations in dihydrofolate synthase confer resistance to para-aminosalicylic acid in clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014,58(3),1479-1487","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=288","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1128\/AAC.01197-08","volume":"53","author":"Mathys V.","year":"2009","unstructured":"Mathys V.; Wintjens R.; Lefevre P.; Bertout J.; Singhal A.; Kiass M.; Kurepina N.; Wang X.M.; Mathema B.; Baulard A.; Kreiswirth B.N.; Bifani P.; Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2009,53(5),2100-2109","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=289","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1128\/jb.179.16.5046-5055.1997","volume":"179","author":"C&#xE1;ceres N.E.","year":"1997","unstructured":"C&#xE1;ceres N.E.; Harris N.B.; Wellehan J.F.; Feng Z.; Kapur V.; Barletta R.G.; Structural activation of the transcriptional repressor EthR from Mycobacterium Tuberculosis by single amino acid change mimicking natural and synthetic ligands. J Bacteriol 1997,179,5046-5055","journal-title":"J Bacteriol"},{"key":"ref=290","doi-asserted-by":"publisher","first-page":"e43467","DOI":"10.1371\/journal.pone.0043467","volume":"7","author":"Chen J.M.","year":"2012","unstructured":"Chen J.M.; Uplekar S.; Gordon S.V.; Cole S.T.; A point mutation in cycA partially contributes to the D-cycloserine resistance trait of Mycobacterium bovis BCG vaccine strains. PLoS One 2012,7(8),e43467","journal-title":"PLoS One"},{"key":"ref=291","doi-asserted-by":"publisher","first-page":"9677","DOI":"10.1073\/pnas.97.17.9677","volume":"97","author":"DeBarber A.E.","year":"2000","unstructured":"DeBarber A.E.; Mdluli K.; Bosman M.; Bekker L.G.; Barry C.E.; III Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2000,97(17),9677-9682","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=292","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1128\/AAC.01030-10","volume":"55","author":"Brossier F.","year":"2011","unstructured":"Brossier F.; Veziris N.; Truffot-Pernot C.; Jarlier V.; Sougakoff W.; Molecular investigation of resistance to the antituberculous drug ethionamide in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011,55(1),355-360","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=293","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/j.1365-2958.2008.06365.x","volume":"69","author":"Vilch&#xE8;ze C.","year":"2008","unstructured":"Vilch&#xE8;ze C.; Av-Gay Y.; Attarian R.; Liu Z.; Hazb&#xF3;n M.H.; Colangeli R.; Chen B.; Liu W.; Alland D.; Sacchettini J.C.; Jacobs W.R.; Jr Mycothiol biosynthesis is essential for ethionamide susceptibility in Mycobacterium tuberculosis. Mol Microbiol 2008,69(5),1316-1329","journal-title":"Mol Microbiol"},{"key":"ref=294","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1128\/AAC.04058-14","volume":"59","author":"Bernard C.","year":"2015","unstructured":"Bernard C.; Veziris N.; Brossier F.; Sougakoff W.; Jarlier V.; Robert J.; Aubry A.; Molecular diagnosis of fluoroquinolone resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2015,59(3),1519-1524","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=295","doi-asserted-by":"publisher","first-page":"1701633","DOI":"10.1183\/13993003.01633-2017","volume":"50","author":"Che Y.","year":"2017","unstructured":"Che Y.; Song Q.; Yang T.; Ping G.; Yu M.; Fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis independent of fluoroquinolone use. Eur Respir J 2017,50(6),1701633","journal-title":"Eur Respir J"},{"key":"ref=296","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.molcel.2006.05.044","volume":"23","author":"Johansen S.K.","year":"2006","unstructured":"Johansen S.K.; Maus C.E.; Plikaytis B.B.; Douthwaite S.; Capreomycin binds across the ribosomal subunit interface using tlyA-encoded 2\u2032-O-methylations in 16S and 23S rRNAs. Mol Cell 2006,23(2),173-182","journal-title":"Mol Cell"},{"key":"ref=297","doi-asserted-by":"publisher","first-page":"e33275","DOI":"10.1371\/journal.pone.0033275","volume":"7","author":"Georghiou S.B.","year":"2012","unstructured":"Georghiou S.B.; Magana M.; Garfein R.S.; Catanzaro D.G.; Catanzaro A.; Rodwell T.C.; Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLoS One 2012,7(3),e33275","journal-title":"PLoS One"},{"key":"ref=298","doi-asserted-by":"publisher","first-page":"20004","DOI":"10.1073\/pnas.0907925106","volume":"106","author":"Zaunbrecher M.A.","year":"2009","unstructured":"Zaunbrecher M.A.; Sikes R.D.; Metchock B.; Shinnick T.M.; Posey J.E.; Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2009,106(47),20004-20009","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=299","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1128\/AAC.01550-10","volume":"55","author":"Campbell P.J.","year":"2011","unstructured":"Campbell P.J.; Morlock G.P.; Sikes R.D.; Dalton T.L.; Metchock B.; Starks A.M.; Hooks D.P.; Cowan L.S.; Plikaytis B.B.; Posey J.E.; Posey J.E.; Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011,55(5),2032-2041","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=300","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1128\/JCM.00330-06","volume":"44","author":"Caws M.","year":"2006","unstructured":"Caws M.; Duy P.M.; Tho D.Q.; Lan N.T.N.; Hoa D.V.; Farrar J.; Mutations prevalent among rifampin- and isoniazid-resistant Mycobacterium tuberculosis isolates from a hospital in Vietnam. J Clin Microbiol 2006,44(7),2333-2337","journal-title":"J Clin Microbiol"},{"key":"ref=301","doi-asserted-by":"publisher","first-page":"e01586","DOI":"10.1128\/mBio.01586-16","volume":"8","author":"Kerantzas C.A.","year":"2017","unstructured":"Kerantzas C.A.; Jacobs W.R.; Origins of combination therapy for tuberculosis: lessons for future antimicrobial development and application. MBio 2017,8(2),e01586-e16","journal-title":"MBio"},{"key":"ref=302","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1128\/AAC.00264-06","volume":"50","author":"Andini N.","year":"2006","unstructured":"Andini N.; Nash K.A.; Intrinsic macrolide resistance of the Mycobacterium tuberculosis complex is inducible. Antimicrob Agents Chemother 2006,50(7),2560-2562","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=303","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/jac\/46.3.391","volume":"46","author":"Bosne-David S.","year":"2000","unstructured":"Bosne-David S.; Barros V.; Verde S.C.; Portugal C.; David H.L.; Intrinsic resistance of Mycobacterium tuberculosis to clarithromycin is effectively reversed by subinhibitory concentrations of cell wall inhibitors. J Antimicrob Chemother 2000,46(3),391-395","journal-title":"J Antimicrob Chemother"},{"key":"ref=304","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1749-6632.2011.05962.x","volume":"1222","author":"Leach K.L.","year":"2011","unstructured":"Leach K.L.; Brickner S.J.; Noe M.C.; Miller P.F.; Linezolid, the first oxazolidinone antibacterial agent. Ann N Y Acad Sci 2011,1222(1),49-54","journal-title":"Ann N Y Acad Sci"},{"key":"ref=305","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1128\/AAC.01113-06","volume":"51","author":"Richter E.","year":"2007","unstructured":"Richter E.; R&#xFC;sch-Gerdes S.; Hillemann D.; First linezolid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2007,51(4),1534-1536","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=306","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1128\/AAC.01189-07","volume":"52","author":"Hillemann D.","year":"2008","unstructured":"Hillemann D.; R&#xFC;sch-Gerdes S.; Richter E.; In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants. Antimicrob Agents Chemother 2008,52(2),800-801","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=307","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1128\/AAC.06227-11","volume":"56","author":"Beckert P.","year":"2012","unstructured":"Beckert P.; Hillemann D.; Kohl T.A.; Kalinowski J.; Richter E.; Niemann S.; Feuerriegel S.; rplC T460C identified as a dominant mutation in linezolid-resistant Mycobacterium tuberculosis strains. Antimicrob Agents Chemother 2012,56(5),2743-2745","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=308","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1159\/000109769","volume":"53","author":"Escribano I.","year":"2007","unstructured":"Escribano I.; Rodr&#xED;guez J.C.; Llorca B.; Garc&#xED;a-Pachon E.; Ruiz M.; Royo G.; Importance of the efflux pump systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid. Chemotherapy 2007,53(6),397-401","journal-title":"Chemotherapy"},{"key":"ref=309","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/1791013a0","volume":"179","author":"Barry V.C.","year":"1957","unstructured":"Barry V.C.; Belton J.G.; Conalty M.L.; Denneny J.M.; Edward D.W.; O\u2019Sullivan J.F.; Twomey D.; Winder F.; A new series of phenazines (rimino-compounds) with high antituberculosis activity. Nature 1957,179(4568),1013-1015","journal-title":"Nature"},{"key":"ref=310","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5935\/0305-7518.19620002","volume":"33","author":"Browne S.G.","year":"1962","unstructured":"Browne S.G.; Hogerzeil L.M.; &#x201C;B 663&#x201D; in the treatment of leprosy. Preliminary report of a pilot trial. Lepr Rev 1962,33(1),6-10","journal-title":"Lepr Rev"},{"key":"ref=311","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/jac\/dkr444","volume":"67","author":"Cholo M.C.","year":"2012","unstructured":"Cholo M.C.; Steel H.C.; Fourie P.B.; Germishuizen W.A.; Anderson R.; Clofazimine: current status and future prospects. J Antimicrob Chemother 2012,67(2),290-298","journal-title":"J Antimicrob Chemother"},{"key":"ref=312","doi-asserted-by":"publisher","first-page":"10276","DOI":"10.1074\/jbc.M110.200501","volume":"286","author":"Yano T.","year":"2011","unstructured":"Yano T.; Kassovska-Bratinova S.; Teh J.S.; Winkler J.; Sullivan K.; Isaacs A.; Schechter N.M.; Rubin H.; Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J Biol Chem 2011,286(12),10276-10287","journal-title":"J Biol Chem"},{"key":"ref=313","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1128\/AAC.00037-14","volume":"58","author":"Hartkoorn R.C.","year":"2014","unstructured":"Hartkoorn R.C.; Uplekar S.; Cole S.T.; Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014,58(5),2979-2981","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=314","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1473-3099(09)70041-6","volume":"9","author":"Orenstein E.W.","year":"2009","unstructured":"Orenstein E.W.; Basu S.; Shah N.S.; Andrews J.R.; Friedland G.H.; Moll A.P.; Gandhi N.R.; Galvani A.P.; Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009,9(3),153-161","journal-title":"Lancet Infect Dis"},{"key":"ref=315","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.tube.2003.08.002","volume":"84","author":"Dony J.F.","year":"2004","unstructured":"Dony J.F.; Ahmad J.; Khen Tiong Y.; Epidemiology of tuberculosis and leprosy, Sabah, Malaysia. Tuberculosis (Edinb) 2004,84(1-2),8-18","journal-title":"Tuberculosis (Edinb)"},{"key":"ref=316","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1183\/09031936.00134712","volume":"42","author":"Falzon D.","year":"2013","unstructured":"Falzon D.; Gandhi N.; Migliori G.B.; Sotgiu G.; Cox H.S.; Holtz T.H.; Hollm-Delgado M.G.; Keshavjee S.; DeRiemer K.; Centis R.; D\u2019Ambrosio L.; Lange C.G.; Bauer M.; Menzies D.; Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013,42(1),156-168","journal-title":"Eur Respir J"},{"key":"ref=317","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1183\/09031936.00188313","volume":"44","author":"Lange C.","year":"2014","unstructured":"Lange C.; Abubakar I.; Alffenaar J.W.C.; Bothamley G.; Caminero J.A.; Carvalho A.C.C.; Chang K.C.; Codecasa L.; Correia A.; Crudu V.; Davies P.; Dedicoat M.; Drobniewski F.; Duarte R.; Ehlers C.; Erkens C.; Goletti D.; G&#xFC;nther G.; Ibraim E.; Kampmann B.; Kuksa L.; de Lange W.; van Leth F.; van Lunzen J.; Matteelli A.; Menzies D.; Monedero I.; Richter E.; R&#xFC;sch-Gerdes S.; Sandgren A.; Scardigli A.; Skrahina A.; Tortoli E.; Volchenkov G.; Wagner D.; van der Werf M.J.; Williams B.; Yew W.W.; Zellweger J.P.; Cirillo D.M.; Management of patients with multidrug-resistant\/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 2014,44(1),23-63","journal-title":"Eur Respir J"},{"key":"ref=318","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1183\/09031936.00125812","volume":"41","author":"Skripconoka V.","year":"2013","unstructured":"Skripconoka V.; Danilovits M.; Pehme L.; Tomson T.; Skenders G.; Kummik T.; Cirule A.; Leimane V.; Kurve A.; Levina K.; Geiter L.J.; Manissero D.; Wells C.D.; Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013,41(6),1393-1400","journal-title":"Eur Respir J"},{"key":"ref=319","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMoa1313865","volume":"371","author":"Diacon A.H.","year":"2014","unstructured":"Diacon A.H.; Pym A.; Grobusch M.P.; de los Rios J.M.; Gotuzzo E.; Vasilyeva I.; Leimane V.; Andries K.; Bakare N.; De Marez T.; Haxaire-Theeuwes M.; Lounis N.; Meyvisch P.; De Paepe E.; van Heeswijk R.P.G.; Dannemann B.; Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014,371(8),723-732","journal-title":"N Engl J Med"},{"key":"ref=320","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/cid\/ciu786","volume":"60","author":"Guglielmetti L.","year":"2015","unstructured":"Guglielmetti L.; Le D&#xFB; D.; Jachym M.; Henry B.; Martin D.; Caumes E.; Veziris N.; M&#xE9;tivier N.; Robert J.; Andrejak C.; Bernard C.; Brossier F.; Chadelat K.; Dautzenberg B.; Jarlier V.; Raskine L.; Rivoire B.; Veziris N.; Appere C.; Assouline P.; Borie R.; Boukari L.; Caseris M.; Caumes E.; Douadi Y.; Dumoulin J.; Duval C.; Faucher J.F.; Gallien S.; Godet C.; Le Grusse J.; Lopes A.; Meynard J.L.; Naccache J.M.; Philippe B.; Richaud C.; Saad H.; Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis 2015,60(2),188-194","journal-title":"Clin Infect Dis"},{"key":"ref=321","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1086\/653115","volume":"51","author":"Jacobson K.R.","year":"2010","unstructured":"Jacobson K.R.; Tierney D.B.; Jeon C.Y.; Mitnick C.D.; Murray M.B.; Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010,51(1),6-14","journal-title":"Clin Infect Dis"},{"key":"ref=322","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1183\/09031936.00035114","volume":"45","author":"Tang S.","year":"2015","unstructured":"Tang S.; Yao L.; Hao X.; Zhang X.; Liu G.; Liu X.; Wu M.; Zen L.; Sun H.; Liu Y.; Gu J.; Lin F.; Wang X.; Zhang Z.; Efficacy Z.; Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J 2015,45(1),161-170","journal-title":"Eur Respir J"},{"key":"ref=323","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1001\/archinte.163.9.1009","volume":"163","author":"Corbett E.L.","year":"2003","unstructured":"Corbett E.L.; Watt C.J.; Walker N.; Maher D.; Williams B.G.; Raviglione M.C.; Dye C.; The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003,163(9),1009-1021","journal-title":"Arch Intern Med"},{"key":"ref=324","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.tube.2003.08.003","volume":"84","author":"Gomez J.E.","year":"2004","unstructured":"Gomez J.E.; McKinney J.D.M.; tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb) 2004,84(1-2),29-44","journal-title":"Tuberculosis (Edinb)"},{"key":"ref=325","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1074\/jbc.M209248200","volume":"278","author":"Smith C.V.","year":"2003","unstructured":"Smith C.V.; Huang C.; Miczak A.; Russell D.G.; Sacchettini J.C.; H&#xF6;ner zu Bentrup K.; Biochemical and structural studies of malate synthase from Mycobacterium tuberculosis. J Biol Chem 2003,278(3),1735-1743","journal-title":"J Biol Chem"},{"key":"ref=326","first-page":"301","volume":"55","year":"2006","unstructured":"Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs worldwide. MMWR Morb Mortal Wkly Rep Centers for Disease Control and Prevention2006,55,301-305","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref=327","first-page":"345","author":"Garay S.M.","year":"2004","unstructured":"Garay S.M.; In Tuberculosis, WNAG 2004,345-394","journal-title":"In Tuberculosis, WNAG"},{"key":"ref=328","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1128\/CMR.8.4.496","volume":"8","author":"Musser J.M.","year":"1995","unstructured":"Musser J.M.; Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev 1995,8(4),496-514","journal-title":"Clin Microbiol Rev"},{"key":"ref=329","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/cid\/cis128","volume":"54","author":"Migliori G.B.","year":"2012","unstructured":"Migliori G.B.; Centis R.; D\u2019Ambrosio L.; Spanevello A.; Borroni E.; Cirillo D.M.; Sotgiu G.; Totally drug-resistant and extremely drug-resistant tuberculosis: the same disease? Clin Infect Dis 2012,54(9),1379-1380","journal-title":"Clin Infect Dis"}],"container-title":["Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573406419666230111111153","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/212575\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573406419666230111111153","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T01:17:04Z","timestamp":1728695824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/212575\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":329,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573406419666230111111153","relation":{},"ISSN":["1573-4064"],"issn-type":[{"value":"1573-4064","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-06-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}